腎と透析　Vol.74　2013年増刊号　腎疾患治療薬マニュアル　2013-14

【総論】

P.13 掲載の参考文献

1) Go AS, Chertow GM, Fan D, et al : Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 : 1296-305, 2004

PubMed

2) Iseki K, Ikemiya Y, Iseki C, et al : Proteinuria and the risk of developing end-stage renal disease. Kidney Int 63 : 1468-74, 2003

PubMed

3) Levey AS, de Jong PE, Coresh J, et al : The definition, classification, and prognosis of chronic kidney disease : a KDIGO Controversies Conference report. Kidney Int 80 : 17-28, 2011

PubMed

4) KDIGOガイドライン http://www.kdigo.org/clinical_practice_guidelines/index.php

 

5) 日本腎臓学会編 : CKD診療ガイド 2012, 東京医学社, 東京, 2012

 

6) Matsuo S, Imai E, Horio M, et al : Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53 : 982-92, 2009

PubMed

7) Horio M, Imai E, Yasuda Y, et al : GFR Estimation Using Standardized Serum Cystatin C in Japan. Am J Kidney Dis 61 : 197-203, 2013

PubMed

8) 腎移植後内科・小児科系合併症の診療ガイドライン 2011 http://www.jscrt.jp/pdf_file/guide2011.pdf

 

P.21 掲載の参考文献

1) KDIGO Clinical Practice Guideline for AKI : Kidney Int Suppl. 2 : 1-115, 2012

 

2) 腎障害患者におけるヨード造影剤使用に関するガイドライン 2012. 東京医学社.

 

【腎疾患に使用する薬剤】

P.26 掲載の参考文献

1) Konstam MA, et al : Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure : the EVEREST Outcome Trial. JAMA 297 : 1319-1331, 2007

PubMed

2) Bakris GL, et al : Renal outcomes with different fixeddose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH) : a prespecified secondary analysis of a randomized controlled trial. Lancet 375 : 1173-1181, 2010

PubMed

3) Ernst ME, et al : Diuretics in the Treatment of Hypertension. Semin Nephrol 31 : 495-502, 2011

PubMed

P.31 掲載の参考文献

1) Hayashi K, Wakino S, Sugano N, Ozawa Y, et al : Ca2+ channel subtypes and pharmacology in the kidney. Circulation Research 100 : 342-353, 2007

PubMed

2) Hayashi K, Homma K, Wakino S, Tokuyama H, et al : T-type Ca channel blockade as a determinant of kidney protection. The Keio Journal of Medicine 59 : 84-95, 2010

PubMed

3) 日本腎臓学会編 : 血圧管理 : 成人. CKD診療ガイド 2012, p67, 東京医学社, 東京, 2012

 

4) Abe M, et al : Comparison between the antiproteinuric effects of the calcium channel blockers benidipine and cilnidipine in combination with angiotensin receptor blockers in hypertensive patients with chronic kidney disease. Expert Opin Investig Drugs 19 : 1027-1037, 2010

 

5) Fujita T, Ando K, Nishimura H, Ideura T, et al : Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic kidney disease. Kidney Int 72 : 1543-1549, 2007

PubMed

P.37 掲載の参考文献

1) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 高血圧治療ガイドライン 2009, イフサイエンス出版, 東京, 2009

 

2) 柏原直樹 : 慢性腎臓病 (CKD) を合併する高血圧の管理 (第5土曜特集高血圧のすべて 2012 : 研究と診療の最前線) - (最新のエビデンスに基づく高血圧診療 2012). 医学のあゆみ 241 : 1200-1207, 2012

 

3) Brenner BM, Cooper ME, de Zeeuw D, et al : Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 : 861-869, 2001

PubMed

4) 柏原直樹 : 血圧コントロールと尿蛋白. 腎と透析 65 : 217-223, 2008

Medical*Online

5) Parving HH, Lehnert H, Brochner-Mortensen J, et al : The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 : 870-878, 2001

PubMed

P.41 掲載の参考文献

1) 岡本研 : 新世代の尿酸生成抑制剤フェブキソスタット-XO阻害機構をアロプリノールと対比する-. 薬理と治療 38 : 955-962, 2010

Medical*Online

2) Kamatani N, Fujimori S, Hada T, et al : An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan : phase 3 clinical study. J Clin Rheumatol 17 (4 suppl 2) : S13-18, 2011

 

3) Becker MA, Schumacher HR, Espinoza L, et al : The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout : the CONFIRMS trial. Arthritis Res Ther 12 : R63, 2010

PubMed

4) Latif WL, Karaboyas A, Tong L, et al : Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population. Clin J Am Soc Nephrol 6 : 2470-2477, 2011

 

5) Hung SI, Chung WH, Lion LB, et al : HLA-B*5801 as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 102 : 4134-4139, 2005

 

P.45 掲載の参考文献

1) Keane WF : Lipids and progressive renal failure. Wien Klin Wochenschr 108 : 420-442, 1996

PubMed

2) Abrass CK : Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol 24 : 46-53, 2004

PubMed

3) Weinberg JM : Lipotoxicity. Kidney Int 70 : 1560-1566, 2006

PubMed

4) 日本腎臓学会編 : CKD診療ガイド 2012, 東京医学社, 東京, 2012

 

P.50 掲載の参考文献

1) Jayne D, et al : A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349 : 36-44, 2003

PubMed

2) Hiemstra TF, et al : Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis : A randomized controlled trial. JAMA 304 (21) : 2381-2388, 2010

PubMed

3) Dooley MA : Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365 : 1886-1895, 2011

PubMed

P.54 掲載の参考文献

1) Gambaro G, et al : Glycosaminoglycan treatment in glomerulonephritis? An interesting option to investigate. J Nephrol 23 : 244-252, 2010

PubMed

2) Taji Y, et al : Meta-analysis of antiplatelet therapy for IgA nephropathy. Clin Exp Nephrol 10 : 268-273, 2006

PubMed

3) Ishii T, et al : Prospective trial of combined therapy with heparin/warfarin and renin-angiotensin system inhibitors in progressive IgA nephropathy. Contrib Nephrol 157 : 114-119, 2007

PubMed

4) Yan SF, et al : The RAGE axis : a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res 106 : 842-853, 2010

 

5) Hansen PM, et al : Effect of low dose heparinon urinary albumin excretion in insulin-dependent diabetes mellitus. Lancet 345 : 421-422, 1995

PubMed

6) Lewis EJ, et al : Sulodexide for kidney protection in type2 diabetes patients with microalbuminuria : a randomized controlled trial. Am J Kidney Dis 58 : 729-736, 2011

 

7) Dolgin ES : As E. coli continues to claim lives, new approaches offer hope. Nat Med 17 (7) : 755, 2011

 

8) Saito H, et al : Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation : results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 5 (1) : 31-41, 2007

PubMed

9) Hirano K, et al : The predictive value of attenuated proteinuria at 1 year after steroid therapy for renal survival in patients with IgA nephropathy. Clin Exp Nephrol 2012 [Epub ahead of print]

 

P.57 掲載の参考文献

1) Levin A, Bakris GL, Molitch M, Smulders M, et al : Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease : results of the study to evaluate early kidney disease. Kidney Int 71 (1) : 31-38, 2007

 

2) Gallagher JC, Rapuri PB, Smith LM : An age-related decrease in creatinine clearance is associated with an increase in number of falls in untreated women but not in women receiving calcitriol treatment. J Clin Endocrinol Metab 92 (1) : 51-58, 2007

 

3) Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K : Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 168 (4) : 397-403, 2008

PubMed

4) Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J, Guinsburg A, et al : Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 74 (8) : 1070-1078, 2008

PubMed

5) Taniguchi M, Tokumoto M, Tsuruya K, Hirakata H, et al : Intravenous calcitriol therapy in an early stage prevents parathyroid gland growth. Nephrol Dial Transplant 23 (11) : 3662-3669, 2008

 

6) Tentori F, Albert JM, Young EW, Blayney MJ, et al : The survival advantage for haemodialysis patients taking vitamin D is questioned : findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 24 (3) : 963-972, 2009

PubMed

P.61 掲載の参考文献

1) Adeney KL, Siscovick DS, Ix JH, et al : Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 20 : 381-387, 2008

PubMed

2) Go AS, Chertow GM, Fan D, et al : Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (13) : 1296-1305, 2004

PubMed

3) Schwarz S, Trivedi BK, Kalantar-Zadeh K, et al : Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol 1 : 825-831, 2006

PubMed

4) Block GA, Klassen PS, Lazarus JM, et al : Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15 : 2208-2218, 2004

PubMed

5) Isakova T, Gutierrez OM, Chang Y, et al : Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 20 : 388-396, 2009

 

6) Daugirdas JT, Chertow GM, Larive B, et al : Effects of Frequent Hemodialysis on Measures of CKD Mineral and Bone Disorder. J Am Soc Nephrol 23 : 727-738, 2012

PubMed

7) 日本透析医学会 : 慢性腎臓病に伴う骨・ミネラル代謝異常の治療ガイドライン. 透析会誌 45 : 301-356, 2012

 

8) KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKDMBD). Kidney Int 76 (suppl 113) : s1-130, 2009

 

P.66 掲載の参考文献

1) Kiss Z, Elliot S, Jedynasty K, et al : Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa : an update of the rationale and clinical impact. Eur J Clin Pharmacol 66 : 331-340, 2010

 

2) 2008年版日本透析医学会「慢性腎臓病患者における腎性貧血治療のガイドライン」. 透析会誌 41 : 661-716, 2008

 

3) Singh AK, Szczech L, Tang KL, et al : CHOIR Investigators : Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 : 2085-2098, 2006

PubMed

4) Drueke TB, Locatelli F, Clyne N, et al : CREATE Investigators : Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 : 2071-2084, 2006

PubMed

5) PfefferMA, Burdmann EA, Chen C-Y, et al : A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361 : 2019-2032, 2009

 

6) Silverberg D, Wexler D, Blum M, et al : The cardiorenal anaemia syndrome : does it exist? Nephrol Dial Transplant 18 (suppl 8) : viii7-viii12, 2003

 

7) Bohlius J, Schmidlin K, Brillant C, et al : Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer : a meta-analysis of randomized trials. Lancet 373 : 1532-1542, 2009

 

8) Szczech LA, Barnhart HX, Inring JK, et al : Secondary analysis of the CHOIR trial epoetin-a dose and achived hemoglobin outcomes. Kidney Int 74 : 791-798, 2008

 

9) Imai E, Yamamoto R, Suzuki H, et al : Incidence of symptomatic stroke and cancer in chronic kidney disease patients treated with epoetins. Clin Exp Nephrol 14 : 445-452, 2010

PubMed

P.70 掲載の参考文献

1) Reff ME, Carner K, Chambers KS, et al : Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83 : 435-445, 1994

PubMed

2) Boross P, Leusen JH : Mechanisms of action of CD20 antibodies. Am J Cancer Res 2 : 676-690, 2012

PubMed

3) Bagga A, Sinha A, Moudgil A : Rituximab in patients with the steroid-resistant nephritic syndrome. N Engl J Med 356 : 2751-2752, 2007

 

4) Nakayama M, Kamei K, Nozu K, et al : Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol 23 : 481-485, 2008

PubMed

5) Kurosu N, Sugiura H, Iwasaki C, et al : Successful use of single-dose rituximab for the maintenance of remission in a patient with steroid-resistant nephritic syndrome. Intern Med 48 : 1901-1904, 2009

 

6) Takei T, Nitta K : Rituximab and minimal change nephrotic syndrome : a therapeutic option. Clin Exp Nephrol 15 : 641-647, 2011

PubMed

7) Kamei K, Ito S, Nozu K, et al : Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 24 : 1321-1328, 2009

PubMed

8) Takei T, Itabashi M, Moriyama T, et al : Effect of single-dose rituximab on steroid-dependent minimalchange nephrotic syndrome in adults. Nephrol Dial Transplant 2012 Dec 13 [Epub ahead of print]

 

【症状に対する薬剤の使用方法】

P.75 掲載の参考文献

1) 日本腎臓学会編 : CKD診療ガイド 2012, 東京医学社, 東京, 2012

 

2) 今井圓裕 : 2. 蛋白尿. 腎と透析 72 (増刊号) : 39-43, 2012

 

3) シュライアー著, 南学正臣・奥田俊洋監訳 : 第14章 蛋白尿とネフローゼ症候群. シュライアー腎臓病と病態生理, pp541-551, メディカル・サイエンス・インターナショナル, 東京, 2011

 

4) 下条文武監修 : 1 蛋白尿. 専門医のための腎臓病学第2版, pp2-9, 医学書院, 東京, 2009

 

P.79 掲載の参考文献

1) 井上秀樹, 冨田公夫 ; 利尿薬の効く浮腫とは. 成人病と生活習慣病 42 (3) : 293-298, 2012

Medical*Online

2) 山村由孝, 藤木浩之 : 水利尿薬の開発と臨床応用. 腎と透析 73 (1) : 52-59, 2012

Medical*Online

3) 北岡建樹 : 浮腫の治療方針. 浮腫, 北畠顕, 島本和明編, pp120-131, 医薬ジャーナル社, 大阪, 2002

 

P.85 掲載の参考文献

1) Manual of Nephrology 5th ed, Schrier RW (ed), Lippincott WW Company, philadelphia, 2000

 

2) 飯野靖彦 : 一目でわかる輸液, 第1版, メディカル・サイエンス・インターナショナル, 東京, 1997

 

3) 黒川清 : 水・電解質と酸塩基平衡-step by stepで考える, 改訂2版, 南江堂, 東京, 2004

 

4) Rose BD, Post TW : Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001

 

5) Sherman RA, Eisinger RP : The use (and misuse) of urinary sodium and chloride measurements. JAMA 247 : 3121, 1982

PubMed

6) Vinayak AG, Levitt J, Gehlbach B, et al : Usefulness of the external jugular vein examination in detecting abnormal central venous pressure in critically ill patients. Arch Intern Med 166 : 2132, 2006

PubMed

7) Dossetor JB : Creatininemia versus uremia. The relative significance of blood urea nitrogen and serum creatinine concentrations in azotemia. Ann Intern Med 65 : 1287, 1966

PubMed

8) McGee S, AbernethyWB 3rd, Simel DL : The rational clinical examination. Is this patient hypovolemic? JAMA 281 : 1022, 1999

 

9) Mange K, Matsuura D, Cizman B, et al : Language guiding therapy : the case of dehydration versus volume depletion. Ann Intern Med 127 : 848, 1997

PubMed

10) 三宅康史, 有賀徹, 井上健一郎, 奥寺敬, 他 : 本邦における熱中症の実態-Heatstroke STUDY 2008 最終報告-. 日救急医会誌 21 : 230-244, 2010

 

P.90 掲載の参考文献

1) Suzuki H, Moriwaki K, Nakamoto H, Sugahara S, et al : Blood pressure reduction in the morning yields beneficial effects on progression of chronic renal insufficiency with regression of left ventricular hypertrophy. Clin Exp Hypertens 24 (1-2) : 51-63, 2002

PubMed

2) Suzuki H, Saruta T : An overview of blood pressure regulation associated with the kidney. Contrib Nephrol 143 : 1-15, 2004

PubMed

3) Verdecchia P, Reboldi GP : Hypertension and microalbuminuria : the new detrimental duo. Blood Press 13 (4) : 198-211, 2004

PubMed

4) Suzuki H, Takenaka T, Kanno Y, Ohno Y, et al : Sodium and kidney disease. Contrib Nephrol 155 : 90-101, 2007

PubMed

5) Suzuki H : Treatment of hypertension in chronic renal insufficiency. Int Med 39 : 773-777, 2000

 

P.95 掲載の参考文献

1) 小田切久八, 池田宇一 : 低血圧の診断. 治療 92 (11) : 2482-2488, 2010

 

2) 井上博他 : 失神の診断・治療ガイドライン. Circulation J 71 : 1049-1114, 2007

 

3) Marik PE : Low-dose dopamine : a systemic review. Intensive Care Med 28 : 877-883, 2002

 

P.100 掲載の参考文献

1) 日本鉄バイオサイエンス学会ガイドライン作成委員会編 : 鉄欠乏・鉄欠乏性貧血の予防と治療のための指針, 第1版, pp14-16, 響文社, 札幌, 2004

 

2) 2008年版 慢性腎臓病患者における腎性貧血治療のガイドライン. 透析会誌 41 (10) : 661-716, 2008

 

3) Nakanishi T, et al : Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations? Clin Exp Nephrol 16 (6) : 819-826, 2012

PubMed

4) Silverberg DS, et al : The importance of anemia and its correction in the management of severe congestive heart failure. Eur J Heart Fail 4 : 681-686, 2002

PubMed

5) Mohanram A, et al : Anemia and end-stage renal disease in patient with type 2 diabetes and nephropathy. Kidney Int 66 : 1131-1138, 2004

PubMed

P.104 掲載の参考文献

1) 日本腎臓学会編 : CKD診療ガイド 2012, 東京医学社, 東京, 2012

 

2) Giovannetti S, Maggiore Q : A low-nitrogen diet with proteins of high biological value for severe chronic uremia. Lancet 1 : 1000-1003, 1964

PubMed

3) Akizawa T, et al : Effect of a Carbonaceous Oral Adsorbent on the Progression of CKD : A Multicenter, Randomized, Controlled Trial. Am J Kidney Dis 54 : 459-467, 2009

PubMed

4) Schulman G, et al : EPPIC-results from two phase III, randomized placebo-controlled, double-blind trials of AST-120 in adults with CKD. Am Society of Nephrology Annual Meeting Abstract 2012

 

P.107 掲載の参考文献

1) 石川三衛 : 中枢性尿崩症. 日本臨牀 59 (suppl 8) : 51-58, 2001

 

2) Rittig S, et al : Identification of 13 new mutations in the vasopressin-neurophysin II gene in 17 kindreds with familial autosomal dominant neurohypophyseal diabetes insipidus. Am J Hum Genet 58 : 107-117, 1996

PubMed

3) Fujiwara TM, Bichet DG : Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol 16 : 2836-2846, 2005

PubMed

P.111 掲載の参考文献

1) The Kidney Disease : Improving Global Outcome : Clinical practice guideline on acute kidney injury 2012. Kidney Int (suppl 2) : 1-138, 2012

 

2) Lameire N, Van Biesen W, Vanholder R : Acute renal failure. Lancet 365 : 417-430, 2005

PubMed

3) Bart BA, Goldsmith SR, Lee KL, et al : Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 367 : 2296-2304, 2012

PubMed

4) Myburgh JA, Finfer S, Bellomo R, et al ; CHEST Investigators ; Australian and NewZealand Intensive Care Society Clinical Trials Group : Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 367 : 1901-1911, 2012

PubMed

5) Bragg-Gresham JL, Fissell RB, Mason NA, et al : Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS). Am J Kidney Dis 49 : 426-431, 2007

PubMed

P.115 掲載の参考文献

1) Abrams P, et al : The standardisation of terminology of lower urinary tract function : report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn 21 : 167-178, 2002

 

2) 本間之夫, 他 : 下部尿路機能に関する用語基準 : 国際禁制学会標準化部会報告. 日排尿機能会誌 14 : 278-289, 2003

Medical*Online

3) Masumori N, et al : Japanese men have smaller prostate volumes but comparable urinary flow rates relative to American men : results of community based studies in 2 countries. J Urol 155 : 1324-1327, 1996

PubMed

4) Hendrix SL, et al : Pelvic organ prolapse in the women's health initiative : Gravity and gravidity. Am J Obstet Gynecol 186 : 1160-1166, 2002

PubMed

5) Hald T : Urodynamics in benign prostatic hypreplasia ; a survey. Prostate 15 (suppl 2) : 69-77, 1989

 

P.118 掲載の参考文献

1) Bultitude M, Rees J : Management of renal colic. BMJ 345 : e5499, Review, 2012

PubMed

2) 吉田修, 伊藤晴夫 : 尿路結石症外来, メジカルビュー社, 東京, 1998

 

【電解質・酸塩基平衡是正のための薬剤の使用方法】

P.122 掲載の参考文献

1) 深川雅史, 柴垣有吾 : より理解を深める! 体液電解質異常と輸液, pp1-87, 中外医学社, 東京, 2007

 

2) 飯野靖彦 : 一目でわかる腎臓, pp34-39, メディカル・サイエンス・インターナショナル, 東京, 2007

 

P.133 掲載の参考文献

1) LeGrand SB, Leskuski D, Zama I : Narrative review : furosemide for hypercalcemia : an unproven yet common practice. Ann Intern Med 149 (4) : 259-263, 2008

PubMed

2) Reid IR, Cornish J : Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev Rheumatol 8 (2) : 90-96, 2011

PubMed

3) Shoback D : Clinical practice. Hypoparathyroidism. N Engl J Med 359 (4) : 391-403, 2008

PubMed

4) Hodsman AB, et al : Parathyroid hormone and teriparatide for the treatment of osteoporosis : a review of the evidence and suggested guidelines for its use. Endocr Rev 26 (5) : 688-703, 2005

PubMed

P.138 掲載の参考文献

1) 日本人の食事摂取基準 (2010年版), II 各論, 1. エネルギー・栄養素, 6. 1. 多量ミネラル, 表 http://www.mhlw.go.jp/shingi/2009/05/dl/s0529-4ag.pdf

 

2) Falcone N, Compagnoni A, Meschini C, et al : Central pontine myelinolysis induced by hypophosphatemia following Wernicke's encephalopathy. Neurol Sci 24 : 407-410, 2004

PubMed

3) Uribarri J : Phosphorus homeostasis in normal health and in chronic kidney disease patients with special emphasis on dietary phosphorus intake. Semin Dial 20 : 295-301, 2007

PubMed

4) Gaasbeek A, Meinders AE : Hypophosphatemia : an update on its etiology and treatment. Am J Med 118 : 1094-1101, 2005

PubMed

P.142 掲載の参考文献

1) 平山智也 : マグネシウムバランスとその異常. 水・電解質 酸塩基平衡の基本, 大平整爾, 伊丹儀友編, pp92-101, 診断と治療社, 東京, 2010

 

2) Jahnen-Dechnet W, Ketteler M : Magnesium basic. Clin Kidney J 5 (suppl 1) : i3-i14, 2012

 

3) Martin KJ, Gonzalez EA, Slatopolsky E : Clinical consequence and management of hypomagnesia. J Am Soc Nephrol 20 : 2291-2295, 2009

 

4) Cunnigham J, Rodriguez M, Messa P : Magnesium in chronic kidney disease stage 3 and stage 4 and in dialysis. Clin Kidney J 5 (suppl 1) : i39-i51, 2012

 

5) Geiger H, Wanner C : Magnesium in disease. Clin Kidney J 5 (suppl 1) : i25-i38, 2012

 

6) Waldman M, Kobrin S : Disorders of magnesium balance ; hypomagnesemia and hypermagnesemia. Current diagnosis and treatment nephrology and hypertension, Lerma EV, Berns JS, Nissenson AR (eds), pp79-87, McGraw Hill, New York, 2009

 

7) Neumar RW, Otto CW, Link MS, et al : 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science. Circulation 122 : S729-S767, 2010

 

P.145 掲載の参考文献

1) Figge J, Jabor A, Kazda A, et al : Anion gap and hypoalbuminemia. Crit Care Med 26 (11) : 1807-1810, 1998

PubMed

2) Shah SN, Abramowitz M, Hostetter TH, et al : Serum bicarbonate levels and the progression of kidney disease : a cohort study. Am J Kidney Dis 54 (2) : 270-277, 2009

PubMed

3) Phisitkul S, Khanna A, Simoni J, et al : Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR. Kidney Int 77 (7) : 617-623, 2010

PubMed

4) de Brito-Ashurst I, Varagunam M, Raftery MJ, et al : Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 20 (9) : 2075-2084, 2009

PubMed

5) Iberti TJ, Leibowitz AB, Papadakos PJ, et al : Low sensitivity of the anion gap as a screen to detect hyperlactatemia in critically ill patients. Crit Care Med 18 (3) : 275-277, 1990

PubMed

6) Kraut JA, Madias NE : Metabolic acidosis : pathophysiology, diagnosis and management. Nat Rev Nephrol 6 (5) : 274-285, 2010

PubMed

7) Cooper DJ, Walley KR, Wiggs BR, et al : Bicarbonate does not improve hemodynamics in critically ill patients who have lactic acidosis. A prospective, controlled clinical study. Ann Intern Med 112 (7) : 492-498, 1990

 

8) Mathieu D, Neviere R, Billard V, et al : Effects of bicarbonate therapy on hemodynamics and tissue oxygenation in patients with lactic acidosis : a prospective, controlled clinical study. Crit Care Med 19 (11) : 1352-1356, 1990

 

9) Gores GJ, Nieminen AL, Fleishman KE, et al : Extracellular acidosis delays onset of cell death in ATP-depleted hepatocytes. Am J Physiol 255 (3 Pt 1) : C315-C322, 1988

 

10) Laffey JG, O'Croinin D, McLoughlin P, et al : Permissive hypercapnia--role in protective lung ventilatory strategies. Intensive Care Med 30 (3) : 347-356, 2004

PubMed

P.149 掲載の参考文献

1) 黒川清 : 水・電解質と酸塩基平衡-step by stepで考える-改訂2版, 南江堂, 東京, 2004

 

2) 深川雅史, 柴垣有吾 : より理解を深める! 体液電解質異常と輸液, 第3版, 中外医学社, 東京, 2007

 

3) Schrier RW : Renal and Electrolyte Disorders, Lippincott-Raven, Philadelphia, 1997

 

4) Callaham, M : Hypoxic hazards of traditional paper bag rebreathing in hyperventilating patients. Ann Emerg Med 18 (6) : 622-628, 1989

PubMed

【症候群に対する薬剤の使用方法】

P.154 掲載の参考文献

1) 金子修三, 山縣邦弘 : 急性糸球体腎炎の治療ガイド. 腎と透析 62 : 465-469, 2007

Medical*Online

2) 尾田高志, 他 : 急性糸球体腎炎. 日本臨牀 新領域別症候群シリーズ No. 17, 腎臓症候群第2版上巻, pp78-81, 2012

 

3) Rodriguez-Iturbe B, et al : Pathofenesis of poststreptococcal glomerulonephritis a century after Clemens von Pirquet. Kidney Int 71 : 1094-1104, 2007

 

4) Oda T, et al : Localization of nephritis-associated pasmin receptor in acute poststreptococcal glomerulonephritis. Hum Pathol 41 : 1276-1285, 2010

 

5) Sawanobori E, et al : A prolonged course of Group A streptococcus-associated nehritis : a mild case of dense deposit disease (DDD)? Clin Nephrol 71 : 703-707, 2009

 

6) 日本腎臓学会腎疾患患者の生活指導・食事療法に関するガイドライン. 日腎会誌 39 (1) : 1997

 

P.158 掲載の参考文献

1) 進行性腎障害に関する調査研究班急速進行性腎炎症候群分科会 : 急速進行性腎炎症候群の診療指針第二版. 日腎会誌 53 : 509-555, 2011

 

2) 急速進行性糸球体腎炎診療指針作成合同委員会 : 急速進行性腎炎症候群の診療指針. 日腎会誌 44 : 55-82, 2002

 

3) Jayne DR, Gaskin G, Rasmussen N, et al : Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18 : 2180-2188, 2007

 

4) Lapraik C, Watts R, Bacon P, et al : BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) 46 : 1615-1616, 2007

PubMed

5) Mukhtyar C, Guillevin L, Cid MC, et al : EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68 : 310-317, 2009

PubMed

6) Chapter 14 : Anti-glomerular basement membrane antibody glomerulonephritis. Kidney Int (suppl 2) : 240, 2012

PubMed

P.163 掲載の参考文献

1) 日本腎臓学会編 : CKD診療ガイド 2012, 東京医学社, 東京, 2012

 

2) Levey AS, Cattran D, Friedman A, et al : Proteinuria as a surrogate outcome in CKD : report of a scientific workshop sponsored by the national kidney foundation and the us food and drug administration. Am J Kidney Dis 54 : 205-226, 2009

PubMed

3) Tsubakihara Y, Gejyo F, Nishi S, et al : High target hemoglobin with erythropoiesis-stumulating agents has advantages in the renal function of non-dialysis chronic kidney disease patietns. Ther Apher Dial 16 : 529-540, 2012

 

4) Badve SV, Brown F, Hawley CM, et al : Challenges of conducting a trial of uric-acid-lowering therapy in CKD. Nat Rev Nephrol 7 : 295-300, 2011

PubMed

5) Kovesdy CP : Metabolic acidosis and kidney disease : does bicarbonate therapy slow the progression of CKD? Nephrol Dial Transplant 27 : 3056-3062, 2012

PubMed

P.167 掲載の参考文献

1) 厚生労働省難治性疾患克服研究事業進行性腎障害に関する調査研究班 難治性ネフローゼ症候群分科会 : ネフローゼ症候群診療指針. 日腎会誌 53 (2) : 78-122, 2011

 

2) KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int (supple 2) : 139-274, 2012

 

3) CKD診療ガイド 2012. 日腎会誌 54 (8) : 1031-1189, 2012

 

【腎疾患に対する薬剤の使用方法】

P.172 掲載の参考文献

1) 厚生労働省難治性疾患克服研究事業進行性腎障害に関する調査研究班難治性ネフローゼ症候群分科会 : ネフローゼ症候群診療指針 [完全版], 東京医学社, 東京, 2012

 

2) Garin EH, Mu W, Arthur JM, Rivard CJ, et al : Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis. Kidney Int 78 : 296-302, 2010

 

3) Takei T, Koike M, Suzuki K, Shirota S, et al : The characteristics of relapse in adult-onset minimalchange nephrotic syndrome. Clin Exp Nephrol 11 : 214-217, 2007

PubMed

4) Waldman M, Crew RJ, Valeri A, Busch J, et al : Adult minimal-change disease : clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol 2 : 445-453, 2007

PubMed

5) Ponticelli C, Edefonti A, Ghio L, Rizzoni G, et al : Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome : a multicentre randomized controlled trial. Nephrol Dial Transplant 8 : 1326-1332, 1993

PubMed

6) 日本小児腎臓病学会 : 小児特発性ネフローゼ症候群薬物治療ガイドライン 1.0版. 日本小児科学会雑誌 109 : 1066-1075, 2005

 

7) Cattran DC, Alexopoulos E, Heering P, Hoyer PF, et al : Cyclosporin in idiopathic glomerular disease associated with the nephritic syndrome : workshop recommendations. Kidney Int 72 : 1429-1447, 2007

 

8) Amemiya N, Takei T, Kojima C, Nokiba H, et al : Induction of remission following a single dose of rituximab alone in a patient with minimal change nephrotic syndrome. Clin Exp Nephrol 15 : 933-6, 2011

 

9) Chaumais MC, Garnier A, Chalard F, PeuchmaurM, et al : Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol. 24 : 1753-5, 2009

PubMed

10) Muso E, Mune M, Fujii Y, Imai E, et al ; K-FLAT study group : Significantly rapid relief from steroidresistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. Nephron 89 : 408-415, 2001

 

11) Eguchi A, Takei T, Yoshida T, Tsuchiya K, et al : Combined cyclosporine and prednisolone therapy in adult patients with the first relapse of minimalchange nephrotic syndrome. Nephrol Dial Transplant 25 : 124-9, 2010

PubMed

12) Imbasciati E, Gusmano R, Edefonti A, Zucchelli P, et al : Controlled trial of methylprednisolone pulses and low dose oral prednisone for the minimal change nephrotic syndrome. Br Med J 291 : 1305-1308, 1985

 

P.175 掲載の参考文献

1) Jalanko H : Congenital nephrotic syndrome. Pediatr Nephrol 24 : 2121-2128, 2009

PubMed

2) Holmberg C, Antikainen M, Ronnholm K, et al : Management of congenital nephrotic syndrome of the Finnish type. Pediatr Nephrol 9 : 87-93, 1995

PubMed

3) Pomeranz A, Wolach B, Bernheim J, et al : Successful treatment of Finnish congenital nephrotic syndrome with captopril and indomethacin. J Pediatr 126 : 140-142, 1995

PubMed

4) Heaton PA, Smales O, Wong W : Congenital nephrotic syndrome responsive to captopril and indomethacin. Arch Dis Child 81 : 174-175, 1999

PubMed

5) Licht C, Eifinger F, Gharib M, et al : A stepwise approach to the treatment of early onset nephrotic syndrome. Pediatr Nephrol 14 : 1077-1082, 2000

 

6) Kovacevic L, Reid CJ, Rigden SP : Management of congenital nephrotic Syndrome. Pediatr Nephrol 18 : 426-430, 2003

PubMed

P.180 掲載の参考文献

1) 堺秀人, 他 : 難治性ネフローゼ症候群 (成人例) の診療指針. 日腎会誌 44 : 751-761, 2002

 

2) D'Agati VD, et al : Pathologic Classification of Focal Segmental Glomerulosclerosis : A Working Proposalproposal. Am J Kidney Dis 43 : 368-382, 2004

PubMed

3) Wei C, et al : Circulating urokinase receptor as a cause of focalsegmental glomerulosclerosis. Nat Med 17 : 952-960, 2011

 

4) 松尾清一, 他 : ネフローゼ症候群診療指針. 日腎会誌 53 : 78-122, 2011

 

5) Nakayama M, et al : Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol 23 : 481-485, 2008

PubMed

P.184 掲載の参考文献

1) 松尾清一, 川村哲也, 城謙輔, 他 : IgA腎症診療指針-第3版-. 日腎会誌 53 : 123-135, 2001

 

2) LV J, Xu D, Perkovic V, et al : Corticosteroid therapy in IgA nephropathy. J AmSoc Nephrol 23 : 1108-1116, 2012

 

3) Pozzi C, Andrulli S, Del Vecchio L, et al : Corticosteroid effectiveness in IgA nephropathy : Long-term results of a randomized, controlled trial. J Am Soc Nephrol 15 : 157-163, 2004

PubMed

4) Hotta O, Miyazaki M, Furuta T, et al : Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis 38 : 736-743, 2001

PubMed

5) Cheng J, Zhang W, Zhang XH, et al : ACEI/ARB therapy for IgA nephropathy : A meta analysis of randomized controlled trials. Int J Clin Pract 63 : 880-888, 2009

PubMed

6) Cheng J, Zhang X, Tian Q, et al : Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy : a meta-analysis. Int J Clin Pract 66 : 917-923, 2012

 

7) Liu XJ, Geng YQ, Xin SN, et al : Antithrombotic Drug Therapy for IgA nephropathy : A meta analysis of randomized controlled controlled trials. Intern Med 50 : 2503-2510, 2011

PubMed

8) Chou HH, Chiou YY, Hung PH, et al : Omega-3 fatty acids ameliorate proteinuria but not renal function in IgA nephropathy : A meta-analysis of randomized controlled trials. Nephron Clin Pract 121 : c30-c35, 2012

 

P.187 掲載の参考文献

1) 横山仁, 田口尚 : 腎臓病総合レジスリーの構築とその解析に関する研究. 進行性腎障害に関する調査研究 平成21年度総括・分担研究報告書 (松尾清一主任研究者), pp23-34, 2010

 

2) Schieppati A, Mosconi L, Perna A, Mecca G, et al : Prognosis and untreated patients with idiopathic membranous nephropathy. N Engl J Med 329 : 85-89, 1993

PubMed

3) 堺秀人, 黒川清, 斉藤喬雄, 椎木英夫, 他 : 難治性ネフローゼ症候群 (成人例) の診療指針. 日腎会誌 44 : 751-761, 2002

 

4) 松尾清一, 今井圓裕, 斉藤喬雄, 他 : ネフローゼ症候群診療指針〔完全版〕. pp60-63, 東京医学社, 東京, 2012

 

P.191 掲載の参考文献

1) Tarshish P, Bernstein J, Tobin JN, et al : Treatment of mesangiocapillary glomerulonephritis with alternate day prednisone a report of the international study of kidney disease in children. Pediatr Nephrol 6 : 123-130, 1992

 

2) Braun MC, West CD, Strife CF, et al : Difference between membranoproliferative glomerulonephritis type 1 and type 3 in long term response to an alternate day prednisone regimen. Am J Kidney Dis 34 : 1022-1032, 1999

 

3) Kazama I, Matsubara M, Ejima Y, et al : Steroid resistance in prolonged type 1 membranoproliferative glomerulonephritis and accelerated disease remission after steroid withdrawal. Clin Exp Nephrol 9 : 62-68, 2005

PubMed

4) Sethis S, Fervenza FC : Membranoproliferative Glomerulonephritis-A New Look at an Old Entity. N Engl J Med 366 : 1119-1131, 2012

 

5) Licht C, Heinen S, Jozsi M, et al : Deletion of Lys224 in regulatory domain 4 of factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int 70 : 42-50, 2006

PubMed

P.195 掲載の参考文献

1) 吉田雅治 : 内科学書改訂第7版, vol. 3, pp458-59, 中山書店, 東京, 2009

 

2) Mills JA, Michel BA, Bloch DA, et al : The American College of Rheumatology 1990 criteria for the classification of Henoch-Schonlein purpura. Arthritis Rheum 33 : 1114-21, 1990

PubMed

3) Ozen S, Ruperto N, Dillon MJ, et al : EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 65 : 936-941, 2006

PubMed

4) Jennette JC, Falk RJ, Bacon PA, et al : 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013

 

5) Hass M : IgA nephropathy and Henoch-Schonlein purpura nephritis. Heptinstall's Pathology of the Kidney, 6th ed, pp423-486, Lippincott & Wilkins, Philadelphia, 2006

 

6) Lau KK, Suzuki H, Novok J, et al : Pathogenesis of Henoch-Schonlein purpura nephritis. Pediatr Nephrol 25 : 19-26, 2010

 

7) Allen AC, Willis FR, Beattie TJ, et al : Abnormal IgA glycosylation in Henoch- Schonlein purpura restricted to the patient with clinical nephritis. Nephrol Dial Transplant 13 : 930-934, 1998

 

P.198 掲載の参考文献

1) 松尾清一, 他 : 厚生労働省特定疾患進行性腎障害に関する調査研究班報告 急速進行性腎炎症候群の診療指針 第2版. 日腎会誌 53 (4) : 509-555, 2011

 

2) 橋本博史 : ANCA関連血管炎の治療指針. 厚生労働省厚生科学特定疾患対策研究事業難治性血管炎に対する調査研究班編, 難治性血管炎の診療マニュアル, p50, 2002

 

3) de Groot K, Harper L, Jayne DR, Flores Suarez LF, et al ; EUVAS (European Vasculitis Study Group) : Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis : a randomized trial. Ann Intern Med. 150 (10) : 670-680, 2009

 

4) Ito-Ihara T, Ono T, Nogaki F, Suyama K, et al : Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis. Nephron Clin Pract 102 (1) : C35-C42, 2006

PubMed

5) 尾崎承一, 他 ; ANCA関連血管炎のわが国における治療法の確立のための多施設共同前向き臨床研究班, 難治性血管炎に関する調査研究班, 進行性腎障害に関する調査研究班 : 難治性症例に対する新たな治療法. ANCA関連血管炎の診療ガイドライン, 厚生労働省難治性疾患克服研究事業, pp73-86, 2011

 

P.201 掲載の参考文献

1) American Diabetes Association : Standards of medical care in diabetes-2013. Diabetes Care 36 (suppl 1) : S11-S66, 2013

 

2) 日本腎臓学会 : CKD診療ガイド 2012, 東京医学社, 東京, 2012

 

3) 馬場園哲也 : 糖尿病における高血圧の治療と管理. 糖尿病の治療マニュアル 第6版 (東京女子医科大学糖尿病センター編), pp330-355, 医歯薬出版, 東京, 2012

 

4) Hase M, Babazono T, Ujihara N, et al : Comparison of spironolactone and trichlormethiazide as add-on therapy to renin-angiotensin blockade for reduction of albuminuria in diabetic patients. J Diabetes Invest (in press)

 

5) Parving HH, Brenner BM, McMurray JJ, et al : Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367 : 2204-2213, 2012

 

P.205 掲載の参考文献

1) 大越忠和, 長谷川一浩, 内木宏延 : アミロイド線維生成沈着機構. 腎と透析 62 : 155-160, 2007

Medical*Online

2) 石原得博 : アミロイドーシスの分類. 腎と透析 62 : 149-153, 2007

Medical*Online

3) 城謙輔, 藤本美香 : アミロイドーシスの病理診断. 腎と透析 62 : 167-175, 2007

Medical*Online

4) 星井嘉信 : ALアミロイドーシスの病態と診断. 腎と透析 62 : 185-187, 2007

Medical*Online

5) 島崎千尋 : ALアミロイドーシスの治療. 医学のあゆみ 229 : 319-324, 2009

Medical*Online

6) Palladini G, Perfetti V, Obici L, Caccialanza R, et al : Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 103 : 2936-2938, 2004

PubMed

7) Comenzo RL, Gertz MA : Autologous stem cell transplantation for primary systemic amyloidosis. Blood 99 : 4276-4282, 2002

PubMed

8) Gertz MA, Lacy MQ, Dispenzieri A, Ansell SM, et al : Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 34 : 1025-1031, 2004

PubMed

9) Skinner M, Sanchorawala V, Seldin DC, Dember LM, et al : High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis : an 8-year study. Ann Intern Med 140 : 85-93, 2004

PubMed

10) Gono T, Matsuda M, Dohi N, Hoshi K, et al : Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation. Intern Med 42 : 72-77, 2003

PubMed

11) Hoshino J, Ubara Y, Sawa N, Sumida K, et al : Clin Exp Nephrol 15 (4) : 486-492, 2011

PubMed

12) Jaccard A, Moreau P, Leblond V, Leleu X, et al : High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis. N Engl J Med 357 : 1083-1093, 2007

PubMed

13) Hoshino J, Ubara Y, Ohashi K, Takemoto F, et al : Pathologic improvement after high-dose melphalan and autologous stem cell transplantation for primary systemic amyloidosis. NDT Plus 6 : 414-416, 2008

PubMed

14) Lachmann HJ, Goodman HJB, Gilbertson JA, Gallimore JR, et al : Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356 : 2361-2371, 2007

PubMed

15) Okuda Y, Takasugi K : Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum 54 : 2997-3000, 2006

PubMed

16) Hattori Y, Ubara Y, Sumida K, Hiramatsu R, et al : Tocilizumab improves cardiac disease in a hemodialysis patient with AA amyloidosis secondary to rheumatoid arthritis. Amyloid 19 : 37-40, 2012

 

17) Rajkumar SV, Kaplan AA, Leung N : Treatment of kidney disease in multiple myeloma. UpToDate, 2013

 

P.208 掲載の参考文献

1) Rose BD, Runyon DA : Diagnosis and treatment of hepatorenal syndrome. UpToDate 2013

 

2) Salerno F, Gerbes A, Gines P, et al : Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 56 (9) : 1310-1318, 2007

PubMed

3) 古市賢吾, 和田隆志 : IV 特殊な病態とその対応 5. 肝疾患で生じる急性腎不全. 日内会誌 99 (5) : 50-55, 2010

 

4) 日本消化器病学会 : 3. 肝腎症候群. 肝硬変診療ガイドライン, 南江堂, 東京, 2010

 

5) 阿部貴弥, 宮坂昭生 : 肝障害とAKD. 腎と透析 70 (3) : 361-366, 2011

Medical*Online

P.213 掲載の参考文献

1) Ramesh S, Mahajan T, Mohan C : Lupus nephritis : current update. Arthritis Research and Therapy 13 : 240-252, 2012

 

2) Uchida K, Nitta K : Recent advance in the treatment of lupus nephritiss. Clin Exp Nephrol : 16 : 202-213, 2012

PubMed

3) Spranger B, Monahan M, Appel GB : Diagnosis and treatment of lupus nephritis flares-an update. Nat Rev Nephrol 8 : 709-717, 2012

 

4) Hahn BH, Mcmahon MA, Wilkinson A, et al : American College of Rhumatology Guideline for screening, treatment and management of lupus nephritis. Arthritis Care Res 64 : 797-808, 2012

 

5) Hruskova Z, Tesar V : Treatment of proliferative lupus nephritis : a slowly changing landscape. Nat Rev Nephrol 7 : 96-109, 2011

PubMed

P.216 掲載の参考文献

1) Helfrich DJ, Banner B, Steen VD, et al : Normotensive renal crisis in systemic sclerosis. Arthritis Rheum 32 : 1128-1134, 1989

PubMed

2) 遠藤平仁 : 強皮症腎クリーゼ (SRC) 高血圧性, 非高血圧性. 日臨免誌 23 : 656-670, 2000

 

3) Gottenberg JE, Merle-Vincent F, Bentaberry F, et al : Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides : a followup report of tolerability and efficacy. Arthritis Rheum 48 : 2019-2024, 2003

PubMed

P.222 掲載の参考文献

1) Scully M, Hunt BJ, et al ; British Committee for Standards in Haematology : Guidelines on the diagno-sis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 158 (3) : 323-335, 2012

 

2) Bobbio-Pallavicini E, Gugliotta L, Centurioni R, Porta C, et al : Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP. Haematologica 82 (4) : 429-435, 1997

 

3) Hickey CA, Beattie TJ : Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. JAMA 165 : 884-889, 2012

 

4) Menne J, Nitschke M, Stingele R, Abu-Tair M, et al : Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104 : H4 induced haemolytic uraemic syndrome : case-control study. BMJ 345 : e4565, 2012

 

5) Ariceta G, Besbas N, Johnson S, Karpman D, et al ; European Paediatric Study Group for HUS : Guideline for the investigation and initial therapy of diarrheanegative hemolytic uremic syndrome. Pediatr Nephrol 24 (4) : 687-696, 2009 doi : 10.1007/s00467-008-0964-1. Epub 2008 Sep 18

 

P.227 掲載の参考文献

1) 斉藤喬雄 : 間質性腎炎. 今日の診断基準, 大田健, 奈良信雄編, pp423-424, 南江堂, 東京, 2007

 

2) Seshan SV, D'Agati VD, Appel GA, et al : Renal disease. Classification and atlas of tubulointerstitial and vascular diseases, pp4-6, Williams & Wilkins, Baltimore, 1999

 

3) 川野充弘, 佐伯敬子, 中島衡, 他 : IgG4関連腎臓病診療指針. 日腎会誌 53 : 1062-1073, 2011

 

4) 小河原悟, 久野敏, 斉藤喬雄 : カルシニューリン阻害薬による腎障害ネフローゼ症候群維持療法の腎障害. 日腎会誌 53 : 615-619, 2011

 

5) 岡崎和一, 川茂幸, 神澤輝実, 他 : IgG4関連疾患包括診断基準 2011. 日内会誌 101 : 795-804, 2012

 

P.231 掲載の参考文献

1) 日本痛風・核酸代謝学会ガイドライン改訂委員会編 : 高尿酸血症・痛風の治療ガイドライン (第2版), メディカルレビュー社, 大阪, 2010

 

2) Hart TC, et al : Mutations of the UMOD gene are responsible for modullary cystic kidney disease 2 and familial juvenile hyperuricaemic nephropathy. J Med Genet 39 : 882-892, 2002

 

3) Hosoya T, Ichida K, Tabe A, et al : Combined therapy using allopurinol and benzbromarone for gout and hyperuricemia complicated with renal disorder. Jpn J Reumatol 4 : 77-90, 1992

 

4) Uetake D, Ohno I, Ichida K, Yamaguchi Y, et al : Effect of Fenofibrate on the Uric Acid Metabolism and Urate Transporter 1. Internal Medicine (in press)

 

5) Iwanaga T, Sato M, Tamai I, et al : Concentrationdependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther 320 : 211-217, 2007

PubMed

P.235 掲載の参考文献

1) Gross O, et al : Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int 63 : 438-446, 2003.

PubMed

2) Gross O, et al : Early angiotensin converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int 81 : 494-501, 2012

PubMed

3) Kaito H, Nozu K, Yoshikawa N, et al : The effect of aldosterone blockade in patients with Alport syndrome. Pediatr Nephrol 21 : 1824-29, 2006

PubMed

4) Temme J, et al : Outcomes of male patients with Alport syndrome undergoing renal replacement therapy. Clin J Am Soc Nephrol 7 : 1969-1976, 2012

PubMed

5) Kashtan E, et al : Clinical practice recommendation for the treatment of Alport syndrome : a statement of the Alport syndrome reaearch collaborative. Pediatr Nephrol 28 : 5-11, 2013

 

P.240 掲載の参考文献

1) Linthorst GE, Germain DP, Hollak CE, et al : Expert opinion on temporary treatment recommendation for Fabry disease during the shortage of ERT. Mol Genet Metab 102 : 99-102, 2011

PubMed

2) Feriozzi S, Schwarting A, Sunder-Plassmann G, et al : Agalsidase alfa slows the decline in renal function in patients with Fabry diasese. Am L Nephrol 29 : 353-361, 2009

 

3) Wilcox WR, Banikazemi M, Guffon N, et al : Longterm safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75 : 65-74, 2004

PubMed

P.245 掲載の参考文献

1) 山本樹生 : 妊娠高血圧症候群. Newエッセンシャル産科学・婦人科学, pp392-397, 医歯薬出版, 東京, 2010

 

2) Moser M, Brown CM, Rose CH, et al : Hypertension in pregnancy : is it time for a new approach to treatment? J Hypertens 30 (6) : 1092-100, 2012

PubMed

3) Seki H, Takeda S, Kinoshita K : Long-term treatment with nicardipine for severe pre-eclampsia. Int J Gynaecol Obstet 76 (2) : 135-141, 2002

PubMed

4) Magee LA, ChamC, Waterman EJ, et al : Hydralazine for treatment of severe hypertension in pregnancy : meta-analysis. BMJ 327 (7421) : 955-960, 2003

 

5) 山本樹生, 荒井清 : Nitroglycerinによる妊娠中毒症高血圧の管理. 産科と婦人科 58 (10) : 1822-1826, 1991

Medical*Online

6) Cooper WO, Hernandez-Diaz S, Arbogast PG, et al : Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 354 (23) : 2443-2451, 2006

PubMed

7) Li DK, Yang C, Andrade S, et al : Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring : a retrospective cohort study. BMJ. 2011 Oct 18 ; 343 : d5931. doi : 10.1136/bmj. d5931.

 

P.250 掲載の参考文献

1) 大澤勲, 富野康日己 : 腎における薬物の排泄機構-腎からの排泄 (水溶性). 日腎会誌 54 : 977-980, 2012

 

2) 吉江文彦, 柴崎敏昭 : 薬剤性腎障害. 腎と透析 53 (臨時増刊号) : 196-199, 2002

 

3) 城謙輔, 小助川英之 : 薬剤性腎障害の病理. 日腎会誌 54 : 958-971, 2012

 

4) 上田志朗 : 薬剤性腎障害診断のアプローチ. 日腎会誌 54 : 950-957, 2012.

 

5) 猪阪善隆 : 尿細管間質性腎炎 (急性・慢性). 今日の治療指針 2012 私はこう治療している, pp535-536, 医学書院, 東京, 2012

 

P.253 掲載の参考文献

1) http://docs.jsdt.or.jp/overview/pdf2011/p11.pdf

 

2) 竹林茂夫 : 腎血管の特殊性. 循環器科 47 : 1-7, 2000

 

3) 金子修三 : 悪性高血圧の治療と腎予後. 臨牀透析 21 (8) : 1119-1126, 2005

 

4) Kitiyakara C, Guzman NJ : Malignant hypertension and hypertensive emergencies. J Am Soc Nephrol 9 (1) : 133-142, 1998

PubMed

5) 星佐弥子, 山口裕, 他 : 悪性腎硬化症の臨床病理学的検討. 日腎会誌 50 (4) : 488-498, 2008

 

6) Akikusa B, Kondo Y, Irabu N, Shigematsu H : Renal Vascular lesions in severe hypertension. Acta Pathol Jpn 33 (2) : 323-331, 1983

PubMed

7) Eddy AA : Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 7 : 2495-2508, 1996

PubMed

8) Okada H, Danoff TM, Kalluri R, et al : Early roll of FSP1 in epithelial-mesenchymal transformation. Am J Physiol 273 : 563-574, 1997

 

9) Schuttert JB, Liu MH, Gliem N, et al : Human renal fibroblasts derived from normal and fibrotic kidneys show differences in increase of extracellular matrix synthesis and cell proliferation upon angiotensin II exposure. Pflugers Arch 446 : 387-393, 2003

PubMed

10) http://www.jpnsh.org/guideline.html

 

11) http://www.jsn.or.jp/

 

12) http://www.kawasaki-m.ac.jp/diabetes/conference/2002guideline.pdf

 

13) http://www.tufu.or.jp/medical/guideline.html

 

14) http://www.j-circ.or.jp/guideline/pdf/JCS2009_hori_d.pdf

 

15) 日本糖尿病学会編 : 科学的根拠に基づく糖尿病診療ガイドライン改訂第2版, 南江堂, 東京, 2007

 

16) 佐中孜 : CKD早期発見・治療ベストガイド, 医学書院, 東京, 2013

 

P.256 掲載の参考文献

1) 山下武廣, 筒井裕之 : 動脈硬化症 : 診断と治療の進歩 IV. 治療の進歩 4. 腎動脈. 日内会誌 102 : 381-391, 2013

 

2) Pascal Meier : Atherosclerotic renal artery stenosis : update on management strategies. Cure Opin Cardiol 26 : 463-471, 2011

 

3) Hirsch AT, et al : ACC/AHA 2005 Guidelines for the Management of Patient with Peripheral Arterial Disease. J Am Coll Cardiol 47 : 1239-1312, 2006

PubMed

4) Textor SC, Lerman LL : State of the Art : Renovascular Hypertension and Ischemic nephropathy. Am J Hypertens 23 (11) : 1159-1169, 2010

 

P.260 掲載の参考文献

1) 日本高血圧学会高血圧治療作成委員会 : 第12章 二次性高血圧. 高血圧治療ガイドライン 2009, pp99-112, ライフサイエンス社, 東京, 2009

 

2) 伊藤貞嘉 : 第5章 腎血管性高血圧症. 二次性高血圧, pp41-51, メディカルレビュー社, 大阪, 2003

 

3) Ritchie J, Green D, Kalra PA : Current views on the management of atherosclerotic renovascular disease. Ann Med 44 (suppl 1) : S98-S110, 2012

 

4) Cheung CM, Patel A, Shaheen N, et al : The effects of statins on the progression of atherosclerotic renovascular disease. Nephron Clin Pract 107 : c35-c42, 2007

PubMed

P.263 掲載の参考文献

1) Antopolsky MM, et al : Renal infarction in the ED : 10-year experience and review of the literature. Am J Emerg Med 30 (7) : 1055-1060, 2012

PubMed

2) 田村功一, 他 : 腎梗塞・コレステロール塞栓症・腎静脈血栓. 腎と透析 72 (増刊号) : 347-351, 2012

 

3) 甘利佳史, 他 : 特発性コレステロール結晶塞栓症による急性腎不全発症後に塞栓の全身散布により死亡した1剖検例. 透析会誌 43 : 87-92, 2010

 

4) 循環器疾患における抗凝固・抗血小板療法に関するガイドライン (2009年改訂版) Guidelines for management of anticoagulant and antiplatelet therapy in cardiovascular (循環器学会ホームページ http://www.j-circ.or.jp/guideline/) disease (JCS 2009

 

5) 日本脳卒中学会脳卒中医療向上・社会保険委員会rt-PA (アルテプラーゼ) 静注療法指針改訂部会 : rt-PA (アルテプラーゼ) 静注療法適正治療指針第二版 (2012年10月). 脳卒中 34 : 443-480, 2012

 

P.267 掲載の参考文献

1) Scolari F, Ravani P : Atheroembolic renal disease. Lancet 375 : 1650-1660, 2010

PubMed

2) Tunick PA, Nayar AC, Goodkin GM, et al : Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque. Am J Cardiol 90 : 1320-1325, 2002

PubMed

3) Scolari F, Ravani P, Pola A, et al : Predictors of renal and patient outcomes in atheroembolic renal disease : a prospective study. J Am Soc Nephrol 14 : 1584-1590, 2003

PubMed

4) Nakayama M, Izumaru K, Nagata M, et al : The effect of low-dose corticosteroids on short- and long-term renal outcome in patients with cholesterol crystal embolism. Ren Fail 33 : 298-306, 2011

 

5) Meyrier A : Cholesterol crystal embolism : diagnosis and treatment. Kidney Int 69 : 1308-1312, 2006

PubMed

6) Tanaka M, Matsuo K, Shoda H, et al : Severe hyperreninemic hypertension associated with spontaneous renal cholesterol crystal embolization. Clin Exp Nephrol 8 : 150-154, 200

 

7) Belenfant X, Meyrier A, Jacquot C : Supportive treatment improves survival in multivisceral cholesterol crystal embolism. Am J Kidney Dis 33 : 840-850, 1999

PubMed

8) 大竹剛靖, 岡真知子, 守矢英和, 他 : 糖尿病性腎症, コレステロール塞栓症に対するLDLアフェレシス. 日本アフェレシス学会雑誌 30 : 85-89, 2011

 

P.270 掲載の参考文献

1) Asghar M, Ahmed K, Shah SS, Siddique MK, et al : Renal vein thrombosis. Eur J Vasc Endovasc Surg 34 : 217-223, 2007

PubMed

2) Velasquez FF, Garcia PN, Ruiz MN : Idiopathic nephritic syndrome of the adult with asymptomatic thrombosis of the renal vein. Am J Nephrol 8 : 457-462, 1988

 

3) Jalandhara N, et al : Nephrogenic systemic fibrosis and gadrinium-containing radiological contrast agents : an update. Clin Pharmacol Ther 89 : 920-923, 2011

 

4) 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2009年改訂版). 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告), 2009

 

P.274 掲載の参考文献

1) Grantham JJ : Clinical practice : Autosomal dominant polycystic kidney disease. N Engl J Med 359 : 1477-1485, 2008

PubMed

2) Johnson AM, Gabow PA : Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. J Am Soc Nephrol 8 : 1560-1567, 1997

PubMed

3) Torres VE, Chapman AB, Devuyst O, et al : Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367 : 2407-2418, 2012

PubMed

4) Torres VE, Harris PC, Pirson Y : Autosomal dominant polycystic kidney disease. Lancet 369 : 1287-1301, 2007

PubMed

P.279 掲載の参考文献

1) 根東義明 : 腎性尿崩症. 日腎会誌 53 (2) : 177-180, 2011

 

2) 神崎晋 : 腎性尿崩症の実態把握と診断・治療指針作成に関する研究 平成23 年度 総括・分担報告書, pp36-41, 2012

 

3) 冨田公夫 : 尿細管性アシドーシス. 専門医のための腎臓病学 (第2版), 医学書院, 東京, pp556-563, 2011

 

4) Brenner BM (ed) : Brenner and Rector's The Kidney. 8th ed, Elsevier, 2008

 

P.282 掲載の参考文献

1) Bartter F, Pronove P, Grill J Jr, et al : Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome. Am J Med 33 : 811-828, 1962

 

2) Simon DB, Karet FE, Hamdan JM, et al : Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat Genet 13 : 183-188, 1996

 

3) Simon DB, Karet FE, Rodriguez-Soriano J, et al : Genetic heterogeneity of Bartter's syndrome revealed by mutations in the K+ channel, ROMK. Nat Genet 14 : 152-156, 1996

 

4) Simon DB, Bindra RS, Mansfield TA, et al : Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III. Nat Genet 17 : 171-178, 1997

PubMed

5) Simon DB, Nelson-Williams C, Bia MJ, et al : Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet 12 : 24-30, 1996

 

6) Birkenhager R, Otto E Shurmann MJ, et al : Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. Nat Genet 29 : 310-314, 2001

 

7) Seyberth HW : An improved terminology and classification of Bartter-like syndromes. Nat Clin Pract Nephrol 4 : 560-567, 2008

PubMed

P.285 掲載の参考文献

1) Gattineni J, Baum M : Genetic disorders of phosphate regulation. Pediatr Nephrol 27 : 1477-1487, 2012

PubMed

2) Chong WH, Molinolo AA, Chen CC, et al : Tumorinduced osteomalacia. Endocr Relat Cancer 18 : R53-77, 2011

PubMed

3) Carpenter TO, Imel EA, Holm IA, et al : A clinician's guide to X-linked hypophosphatemia. J Bone Miner Res 26 : 1381-1388, 2011

 

4) Alon US, Levy-Olomucki R, Moore WV, et al : Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. Clin J Am Soc Nephrol 3 : 658-664, 2008

PubMed

5) Yavropoulou MP, Kotsa K, Psarrakou AG, et al : Cinacalcet in hyperparathyroidism secondary to Xlinked hypophosphatemic rickets : case report and brief literature review. Hormones 9 : 274-278, 2010

 

6) Aono Y, Yamazaki Y, Yasutake J, et al : Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J BoneMiner Res 24 : 1879-1888, 2009

PubMed

P.289 掲載の参考文献

1) Liddle GW, et al : A familial renal disorder stimulating primary aldosteronism but with negligible aldosterone secretion. Trans Assoc Am Physicians 76 : 199-213, 1963

 

2) Findling JW, et al : Liddle's syndrome : Prospective genetic screening and suppressed aldosterone secretion in an extended kindred. J Clin Endocrinol Metab 82 : 1071-1074, 1997

 

3) Gordon RD, et al : Hypertension and severe hyperkalemia associated with suppression of renin and aldosterone and completely reversed by dietary sodium restriction. Australas Ann Med 19 : 287-294, 1970

 

4) Boyden LM, et al : Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature 482 : 98-102, 2012

PubMed

5) Uchida S : Pathophysiological roles of WNK kinases in the kidney. Pflugers Arch 460 : 695-702, 2010

PubMed

P.292 掲載の参考文献

1) Magen D, Berger L, Coady MJ, et al : A loss-of-function mutation in NaPi-IIa and renal Fanconi's syndrome. N Engl J Med 362 : 1102-1109, 2010

 

2) Loi M : Lowe syndrome. Orphanet J Rare Dis 1 : 16, 2006

PubMed

3) Lowe M : Structure and function of the Lowe syndrome protein OCRL1. Traffic 6 : 711-719, 2005

PubMed

4) Coon BG, Hernandez V, Madhivanan K, et al : The Lowe syndrome protein OCRL1 is involved in primary cilia assembly. Hum Mol Genet 21 : 1835-1847, 2012

PubMed

5) Gahl WA, Bernardini I, Dalakas M, et al : Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest 81 : 549-560, 1988

PubMed

6) Watanabe T, Yoshikawa H, Yamazaki S, et al : Secondary renal Fanconi syndrome caused by valproate therapy. Pediatr Nephrol 20 : 814-817, 2005

PubMed

7) Ruellas AC, Pithon MM, dos Santos RL, et al : Orthodontic treatment of a patient with Lowe syndrome. Am J Orthod Dentofacial Orthop 140 : 562-568, 2011

PubMed

P.297 掲載の参考文献

1) Wein AJ, Kavoussi AW, Novick AC, Partin AW, et al : Campbell-Walsh Urology, 10th ed, pp1087-1121, Saunders, Philadelphia, 2012

 

2) van Nieuwkoop C, Bonten TN, van't Wout JW, et al : Risk factors for bacteremia with uropathogen not cultured from urine in adults with febrile urinary tract infection. Clin Infect Dis 50 : e69-e72, 2012

 

3) Takahashi S, Kurimura Y, Takeyama K, et al : Efficacy of treatment with carbapenems and thirdgeneration cephalosporins for patients with febrile complicated pyelonephritis. J Infect Chemother 15 : 390-395, 2009

PubMed

P.301 掲載の参考文献

1) Bailey RR : The relationship of vesico-ureteric reflux to urinary tract infection and chronic pyelonephritisreflux nephropathy. Clin Nephrol 1 : 132, 1973

PubMed

2) Peters C, Rushton HG : Vesicoureteral reflux associated renal damage : congenital reflux nephropathy and acquired renal scarring. J Urol 184 : 265, 2010

PubMed

3) Peters CA, Skoog SJ, Arant BS Jr, et al : Summary of the AUA Guideline on Management of Primary Vesicoureteral Reflux in Children. J Urol 184 : 1134, 2010

 

4) 近田龍一郎, 坂井清英 : 逆流性腎症Update. Urology View 7 : 38, 2009

Medical*Online

5) Ardissino G, Avolio L, Dacco V, et al : Long-term outcome of vesicoureteral reflux associated chronic renal failure in children. Data from the ItalKid Project. J Urol 172 : 305, 2004

PubMed

P.305 掲載の参考文献

1) Warren JW, Abrutyn E : Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Disease Society in America (IDSA) : Clin Infect Dis 29 : 745-758, 1999

PubMed

2) Naber KG, Bergman B : EAU guidelines on the management of urinary and male genital tract infections. UrinaryTract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). Eur Urol, 2006. http://www.uroweb.org/nc/professional-resources/guidelines/online/

 

3) JAID/JSC感染症治療ガイド委員 : JAID/JSC感染症治療ガイド 2011. 日本感染症学会, ライフサイエンス出版, 東京, 2012

 

P.308 掲載の参考文献

1) 日本間質性膀胱炎研究会ガイドライン作成委員会 : 間質性膀胱炎診療ガイドライン. pp20-65, ブラックウエルパブリッシング, 東京, 2007

 

2) Jellheden B, Norrby RS, Sandberg T : Symptomatic urinary tract infection in women in primary health care. Bacteriological, clinical and diagnostic aspects in relation to host response to infection. Scand J Prim Health Care 14 (2) : 122-128, 1996

PubMed

3) JAID/JSC感染症治療ガイド委員会 : JAID/JSC感染症治療ガイド 2011, pp152-154, ライフサイエンス, 東京, 2012

 

4) Gupta K, Hooton TM, Naber KG, Wullt B, et al : International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women : A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52 : e103-120, 2011

 

5) Grabe M (Chairman), Bjerklund-Johansen TE, Botto H, Wullt B, et al : Guidelines on Urological Infections. pp15-24, 2011 : http://www.uroweb.org/gls/pdf/15_Urological_Infections.pdf

 

P.316 掲載の参考文献

1) 濱砂良一 : 男子尿道炎の診断と治療. 西日本泌尿器科 73 (8) : 391-403, 2011

Medical*Online

2) 感染症治療ガイド委員会 : JJ. JAID/JSC感染症治療ガイド 2011, ライフサイエンス, 東京, 2012

 

3) 岩破一博 : 女性性器感染症, 岩破一博編, 医薬ジャーナル, 東京, 2012

 

4) 松本哲朗, 野口靖之, 田中正利, 小野寺昭一, 他 : 淋菌感染症性感染症診断・治療ガイドライン 2011. 日本性感染症学会誌 22 (1 suppl) : 52-59, 2011

 

5) 三鴨廣繁, 高橋聡, 野口昌良, 清田浩 : 性器クラミジア感染症性感染症診断・治療ガイドライン 2011. 日本性感染症学会誌 22 (1 suppl) : 60-64, 2011

 

P.320 掲載の参考文献

1) Turk C, Knoll T, Petrik A, Sarica K, et al : http://www.uroweb.org/gls/pdf/20_Urolithiasis_LR%20March%2013%202012.pdf

 

2) Grosjean R, Sauer B, Guerra RM, Daudon M, et al : Characterization of human renal stones with MDCT : advantage of dual energy and limitations due to respiratory motion. AJR Am J Roentgenol 190 : 720-728, 2008

PubMed

3) 日本泌尿器科学会, 日本Endourology・ESWL学会, 日本尿路結石症学会編 : 尿路結石症診療ガイドライン, pp52-83, 金原出版, 東京, 2002

 

P.323 掲載の参考文献

1) 日本泌尿器科学会編 : 前立腺肥大症診療ガイドライン, リッチヒルメディカル, 東京, 2011

 

2) 日本排尿機能学会男性下部尿路症状診療ガイドライン作成委員会 : 男性下部尿路症状診療ガイドライン, ブラックウエルパブリッシング, 東京, 2008

 

3) Koiso K, Akaza H, Kikuchi K, et al : Pharmacokinetics of tamsulosin hydrochloride in patients with renal impairment : effects of alpha 1-acid glycoprotein. J Clin Pharmacol 36 : 1029-1038, 1996

PubMed

4) 高木信嘉, 竹田和義, 池田弓子, 他 : 腎機能低下を伴う高血圧症患者および腎機能正常な本態性高血圧患者におけるNaftopidilの血中薬物動態. 臨床医薬 8 : 109-122, 1992

 

5) 清水智司, 宮下格, 松原靖人, 他 : シロドシンの臨床成績紹介-薬物動態を中心に-. 薬学雑誌 126 (増刊号) : 257-263, 2006

 

P.327 掲載の参考文献

1) 日本泌尿器科学会編 : 腎癌診療ガイドライン, 金原出版, 東京, 2011

 

2) 日本泌尿器科学会編 : 膀胱癌診療ガイドライン, 医学図書出版, 東京, 2009

 

3) D'Amico AV, Whittington R, Malkowicz SB, et al : Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 : 969-974, 1998

 

4) 日本泌尿器科学会編 : 前立腺癌診療ガイドライン, 金原出版, 東京, 2012

 

5) Cooperberg MR, Hinotsu S, Namiki M, et al : Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol 27 : 4306-4313, 2009

PubMed

【透析患者に対する薬の使い方】

P.328 掲載の参考文献

1) Seldin and Giebisch's The kidney, 4th ed, pp1135-1139, Academic press, UT, 2007

 

2) Kuriyama S, et al : Effect of cilazapril on hyperdipsia in hemodialyzed patients. Blood Purif 14 (1) : 35-41, 1996

PubMed

3) DeCastro JM : The relation of spomtaneous macronutrient and sodium intake with fluid ingestion and thirst in humans. Physiol Behav 49 : 513-519, 1991

 

P.336 掲載の参考文献

1) Joki N, Hase H, Nakamura R, Yamaguchi T : Onset of coronary artery disease prior to initiation of haemodialysis in patients with end-stage renal disease. Nephrol Dial Transplant 12 : 718-723, 1997

PubMed

2) Herzog CA, Littrell K, Arko C, Frederick PD, et al : Clinical characteristics of dialysis patients with acute myocardial infarction in the United States : a collaborative project of the United States Renal Data System and the National Registry of Myocardial Infarction. Circulation 116 : 1465-1472, 2007

 

3) 日本循環器学会 : 急性冠症候群の診療に関するガイドライン (2007年改訂版) http://www.j-circ.or.jp/guideline/pdf/JCS2007_yamaguchi_h.pdf

 

4) 日本透析医学会 : 血液透析患者における心血管合併症の評価と治療に関するガイドライン. 透析会誌 44 : 337-425, 2011

 

5) Kuo CC, Lee CT, Lee IM, Ho SC, et al : Risk of herpes zoster in patients treated with long-term hemodialysis : a matched cohort study. Am J Kidney Dis 59 : 428-433, 2012

 

P.340 掲載の参考文献

1) 平田純生, 他 : 透析患者への投薬ガイドブック改訂2版, じほう, 東京, 2009

 

P.344 掲載の参考文献

1) 久木田和丘, 他 : 2011年版社団法人日本透析医学会「慢性血液透析用バスキュラーアクセスの作製および修復に関するガイドライン」. 透析会誌 44 : 855, 2011

 

2) 室谷典義, 佐藤純彦 : 血管痛. 改訂第2版血液透析施行時のトラブル・マニュアル, pp182-188, 日本メディカルセンター, 東京, 2008

 

3) 住谷昌彦, 柴田政彦, 他 : 本邦におけるCRPSの判定指標. 日臨麻会誌 30 : 420, 2010

Medical*Online

P.348 掲載の参考文献

1) Yamamoto S, Kazama JJ, Narita I, et al : Recent progress in understanding dialysis-related amyloidosis. Bone 45 (suppl 1) : S39-S42, 2009

 

2) 久野木順一 : 透析脊椎症の病態と治療. 腎と透析64別冊腎不全外科 2008 : 8-13, 2008

 

3) 下条文武, 木村秀樹, 川口良人 : 透析アミロイド症に対する少量ステロイド治療の現況. 透析会誌 31 : 73-78, 1998

 

P.352 掲載の参考文献

1) Parisi L, Pierelli F, Amabile G, et al : Muscular cramps : proposals for a new classification. Acta Neurol Scand 107 (3) : 176-186, 2003

PubMed

2) Hung CY, Chen YL, Chen CS, et al : Association of leptin with hemodialysis-related muscle cramps : a cross-sectional study. Blood Purif 27 (2) : 159-164, 2009

PubMed

3) Hyodo T, Taira T, Takemura T, et al : Immediate effect of Shakuyaku-kanzo-to on muscle cramp in hemodialysis patients. Nephron Clin Pract 104 (1) : c28-32, 2006

PubMed

4) Lynch KE, Feldman HI, Berlin JA, et al : Effect of Lcarnitine on dialysis-related hypotension and muscle cramps : a meta-analysis. Am J Kidney Dis 52 (5) : 962-971, 2008

PubMed

5) Khajehdehi P, Mojerlou M, Behzadi S, et al : A randomized, double-blind, placebo-controlled trial of supplementary vitamin E, C and their combination for treatment of haemodialysis cramps. Nephrol Dial Transplant 16 (7) : 1448-1451, 2001

 

6) El-Hennaway AS, Zaib S : A selected controlled trial of supplementary vitamin E for treatment of muscle cramps in hemodialysis patients. Am J Ther 17 (5) : 455-459, 2010

 

7) Al-Jondeby MS, Cabaguing IT, Paiarillo AA, et al : Comparative crossover controlled study using polysulphone and vitamin E coated dialyzers. Saudi Med J 24 (3) : 265-268, 2003

 

8) Chan P, Huang TY, Chen YJ, et al : Randomized, double-blind, placebo-controlled study of the safety and efficacy of vitamin B complex in the treatment of nocturnal leg cramps in elderly patients with hypertension. J Clin Pharmacol 38 (12) : 1151-1154, 1998

PubMed

9) Oguma S, Ando I, Hirose T, et al : Biotin ameliorates muscle cramps of hemodialysis patients : a prospective trial. Tohoku J Exp Med 227 (3) : 217-223, 2012

PubMed

P.356 掲載の参考文献

1) 石川和夫 : 高齢者のめまい・平衡障害. 綜合臨床 57 : 140-142, 2008

 

2) 井田正博 : 脳梗塞超急性期のMR診断. 臨床画像 16 : 492-506, 2000

 

3) 堀井新 : メイロンがめまいに奏効する理由は. 耳鼻咽喉科・頭頸部外科クリニカルトレンド Part 2, pp132-133, 中山書店, 東京, 1998

 

4) 武田憲昭 : 制吐薬. JOHNS 16 : 1311-1313, 2000

 

P.361 掲載の参考文献

1) 清水利彦, 天野隆弘 : 意識障害の原因疾患とその鑑別. 内科 97 : 768-775, 2006

 

2) 谷脇考恭, 吉良潤一 : 内科でよくみる意識障害の治療. 臨牀と研究 82 : 1803-1807, 2005

Medical*Online

3) 鶴屋和彦 : 透析トラブルQ&A 意識障害の原因と対策について教えてください. 腎と透析 64 : 658-662, 2008

 

4) Tatsumoto N, Fujisaki K, Nagae H, et al : Reversible posterior leukoencephalopathy syndrome in a patient with severe uremic encephalopathy. Clin Nephrol 74 : 154-158, 2010

 

5) 藤崎毅一郎, 平方秀樹 : 不均衡症候群. 透析療法辞典 (第2版) : 198-199, 2009

 

6) Ubara Y, Hoshino J, Tagami T, et al : Hemodialysisrelated portal-systemic encephalopathy. Am J Kidney Dis 44 : e38-e42, 2004

PubMed

7) Paraiso V, Francos M, Rodriguez-Berzosa F, et al : Portosystemic encephalopathy in a patient treated with peritoneal dialysis. Am J Kidney Dis 49 : 854-858, 2007

 

P.370 掲載の参考文献

1) Durack DT, Street AC : Fever of unknown origin--reexamined and redefined. Curr Clin Top Infect Dis 11 : 35-51, 1991

PubMed

2) Evers J : Approach to fever in dialysis patients. Nephron 69 : 110, 1995

PubMed

3) 平田純生, 和泉智, 古久保拓 : 透析患者への投薬ガイドブック改訂2版, じほう, 東京, 2009

 

P.374 掲載の参考文献

1) Wang JY, Chen JD, et al : Development of refractory ascites during amiodarone therapy in a hemodialysis patient with nephrogenic and cardiogenic ascites. Ren Fail 34 (8) : 1033-1036, 2012

 

2) Furukawa H, Ohkado A, et al : Clinical experience with intravenous administration of nifekalant hydrochloride for ventricular tachycardia in a hemodialysis patient after open heart surgery. Kyobu Geka 63 (11) : 988-991, 2010

 

3) Chan KE, Hakim RM, et al : Digoxin associates with mortality in ESRD. J Am Soc Nephrol 21 (9) : 1550-1559, 2010

PubMed

4) Reiffel JA, Appel G : Importane of QT interval determination and renal function assessment during antiarrhythmic drug therapy. J Cardiovasc Pharmacol Ther 6 (2) : 111-119, 2001

 

5) Kaji T, Naruse T, et al : Clinical pharmacokinetics and effects of an oral sustained-release preparation of disopyramide prescribed for patients undergoing maintenance hemodialysis. Blood Purif 18 (1) : 55-58, 2000

PubMed

P.377 掲載の参考文献

1) 日本循環器学会, 他 : 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告), 不整脈薬物治療に関するガイドライン (JCS2009). www.j-circ.or.jp/guideline/pdf/jcs2009_kodama_h.pdf

 

2) Saito D, Matsubara K, et al : Effects of oral theophyline on sick sinus syndrome. J Am Coll Cardiol 21 : 1199-1204, 1993

 

3) Atarashi H, Endoh Y, et al : Chronic effects of cilostazol, a new antithrombotic agent, in patients with bradyarrhythmias. J Cardiovasc Pharmacol 31 : 534-539, 1998

 

4) 平田純生他 : 透析患者への投薬ガイドブック改訂第2版. じほう, 東京, 2009

 

5) 日本透析医学会, 他 : 血液透析患者における心血管合併症の評価と治療に関するガイドライン. 透析会誌 44 (5) : 337-425, 2011

 

P.382 掲載の参考文献

1) 中井滋, 他 : わが国の慢性透析療法の現況 (2005年12月31日現在). 透析会誌 40 : 1-30, 2007

 

2) 日本透析医学会 : 血液透析患者における心血管合併症の評価と治療に関するガイドライン 第2章 血圧異常. 透析会 誌44 : 358-368, 2011

 

3) K/DOQI Workgroup : K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 45 (suppl 3) : S1-153, 2005

 

4) Tai DJ, Lim TW, James MT, et al : Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis : a meta-analysis. Clin J Am Soc Nephrol 5 : 623-630, 2010

PubMed

5) Moriya H, Ohtake T, Kobayashi S : Aortic stiffness, left ventricular hypertrophy and weekly averaged blood pressure (WAB) in patients on haemodialysis. Nephrol Dial Transplant 22 : 1198-1204, 2007

PubMed

P.386 掲載の参考文献

1) 日本透析医学会 : 血液透析患者における心血管合併症の評価と治療に関するガイドライン 第8章 末梢動脈疾患. 透析会誌 44 (5) : 412-418, 2011

 

2) Taniguchi T, Ejiri K, and Baba S : Improvement of autonomic neuropathy after mecobalamin treatment in uremic patients on hemodialysis. Clin Ther 9 : 607-614, 1987

 

3) 樋口輝美, 山崎俊男, 水野真理, 他 : 透析患者の末梢性神経障害性疼痛に対してのプレガバリン (商品名 : リリカ(R)) の有用性と安全性の検討. 透析会誌 45 : 559-566, 2012

 

4) 安宅謙, 丸山弘樹 : 手根管症候群. 腎臓症候群 (第2版) 下. 日本臨牀 (別冊) : 206-209, 2012

 

5) 安田斎 : 糖尿病性ニューロパチーの病態と治療. 臨床神経 49 : 149-157, 2009

 

6) Hotta N, Akanuma Y, Kawamori R, et al : Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy Diabetes Care 29 : 1538-1544, 2006

PubMed

P.392 掲載の参考文献

1) 日本透析医学会 : 2008年版 慢性腎臓病患者における腎性貧血治療のガイドライン. 透析会誌 41 : 661-716, 2008

 

2) Besarab A, Bolton WK, Browne JK, et al : The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 339 : 584-90, 1998

PubMed

3) 平澤由平, 鈴木正司, 伊丹儀友, 他 : 血液透析患者の腎性貧血に対する遺伝子組換えヒトエリスロポエチン製剤 (rHuEPO) 治療における維持Ht値と生命予後に関する大規模調査 (rHuEPO特別調査). 透析会誌 36 : 1265-1272, 2003

 

4) Eckardt KU, Kim J, Kronenberg F, et al : Hemoglobin variability does not predict mortality in European hemodialysis patients. J Am Soc Nephrol 21 : 1765-1775, 2010

 

5) Gilbertson DT, Ebben JP, Foley RN, et al : Hemoglobin level variability : associations with mortality. Clin J Am Soc Nephrol 3 : 133-138, 2008

PubMed

6) Lau JH, Gangji AS, Rabbat CG, et al : Impact of haemoglobin and erythropoietin dose changes on mortality : a secondary analysis of results from a randomized anaemia management trial. Nephrol Dial Transplant 25 : 4002-4009, 2010

PubMed

P.396 掲載の参考文献

1) Cines DB, Bussel JB, Liebman HA, et al : The ITP syndrome : pathogenic and clinical diversity. Blood 113 : 6511-6521, 2009

PubMed

2) Aster RH, Bougie DW : Drug-induced immune thrombocytopenia. N Engl J Med 357 : 580-587, 2007

PubMed

3) Wiestner A, Cho HJ, Asch AS, et al : Rituximab in the treatment of acquired factor VIII inhibitors. Blood 100 : 3426-3428, 2002

PubMed

4) Holden RM, Harman GJ, Wang M, et al : Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol 3 : 105-110, 2008

PubMed

P.400 掲載の参考文献

1) Sands JJ, Kotanko P, Segal JH, et al : Effects of citrate acid concentrate (citrasateR) on heparin N requirements and hemodialysis adequacy : a multicenter, prospective noninferiority trial. Blood Purif 33 (1-3) : 199-204, 2012

PubMed

2) Kaufman JS, O'connor TH, Zahang JH, et al : Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 14 : 2313-2321, 2003

 

3) Dixon BS, Beck GJ, Vazquez MA, et al : Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med 360 : 2191-2201, 2009

PubMed

4) Chan KE, Lazarus JM, Thadhani R, Hakim RM : Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 20 (10) : 2223-2233, 2009

PubMed

P.403 掲載の参考文献

1) 財団法人日本消化器病学会 : 消化性潰瘍診療ガイドライン, 南江堂, 東京, 2009

 

2) 財団法人日本消化器病学会 : 胃食道逆流症診療ガイドライン, 南江堂, 東京, 2009

 

3) 渡辺俊雄, 他 : 潰瘍性病変 2) 薬剤起因性病変アスピリンを含む抗血小板薬. GI Res 18 (6) : 33-38, 2010

 

4) 清水誠治 : 急性出血性直腸潰瘍と宿便性潰瘍. 日本大腸肛門病会誌 54 : 955-959, 2001

 

P.407 掲載の参考文献

1) 大平整爾, 阿部憲司, 他 : 血液透析患者の虚血性大腸炎手術例の分析-アンケート集計124例を中心に-. 腎と透析40別冊腎不全外科 '96 : 8-23, 1996

 

2) Longstreet GF, Thompson WG, Chewy WD, et al : Functional bowel disorders. Gastroenterology 130 : 1480-1491, 2006

 

3) 西原舞, 平田純生, 他 : 透析患者の便秘症についての実態調査. 透析会誌 37 (10) : 1887-1892, 2004

 

4) 西原舞, 他 : 臨床所見・徴侯からのアブローチ 6 下痢, 便秘. 臨牀透析 24 : 808-810, 2008

 

P.410 掲載の参考文献

1) 新田孝作 : 血液浄化療法に関連した医学の基礎知識. 免疫. 血液浄化療法ハンドブック改訂第3版, 透析療法合同専門委員会編著, pp45-50, 協同医書出版社, 東京, 2004

 

2) 神谷康司, 中林公正 : 血液浄化療法に関連した医学の基礎知識. 免疫. 血液浄化療法ハンドブック改訂第2版, 透析療法合同専門委員会編著, pp56-64, 協同医書出版社, 東京, 1998

 

3) 秋葉隆 : 腎不全患者の病態生理. 感染症. 血液浄化療法ハンドブック改訂第3版, 透析療法合同専門委員会編著, pp287-289, 協同医書出版社, 東京, 2004

 

4) 山中智恵 : 合併症と併発症. 血液学的合併症. 細胞性免疫. 透析療法事典第2版, 中本雅彦, 佐中孜, 秋澤忠男編, pp274-275, 医学書院, 東京, 2009

 

5) 黒田満彦 : 透析患者の合併症に対するくすりの使い方. 対症療法. 免疫不全. 腎と透析 27 (臨時増刊号) : 396-397, 1989

 

6) 山中智恵 : 合併症と併発症. 血液学的合併症. 液性免疫. 透析療法事典第2版, 中本雅彦, 佐中孜, 秋澤忠男編, pp273-274, 医学書院, 東京, 2009

 

7) 佐藤昌志, 木暮照子 : 透析患者に対するくすりの使い方. 対症療法. 免疫不全. 腎と透析 53 (増刊号) : 403-405, 2002

 

P.413 掲載の参考文献

1) 平井良治, 池田稔 : 味覚障害診療ガイドライン作成に向けて 味覚障害の診断 (総説). 口腔・咽頭科 25 (1) : 1-5, 2012

 

2) 愛場庸雅 : 味覚障害診療ガイドライン作成に向けて味覚障害の治療法とその効果 (総説). 口腔・咽頭科 25 (1) : 11-16, 2012

 

3) 重篤副作用疾患別対応マニュアル 薬物性味覚障害, 厚生労働省, 平成23年3月

 

4) 市村恵一 : 〔日常診療でよくみる症状・病態-診断の指針・治療の指針-〕耳鼻咽喉の異常 嗅覚異常. 綜合臨牀 60 : 1029-1032, 2011

 

5) 深澤啓二郎 : 嗅覚障害の治療. 脳21 9 (2) : 171-176, 2006

Medical*Online

P.420 掲載の参考文献

1) 田中達也, 桃崎宣明, 後藤公文, 本田英一郎 : 脳主幹動脈閉塞に伴う広範脳梗塞に対する五苓散の使用経験. 漢方医学 36 (2) : 159-163, 2012

 

2) 松宮輝彦, 原一恵, 外山由夏 : 臨床医のための治療薬剤Q&A. 診断と治療 96 (5) : 979-984, 2008

 

3) 日本緑内障学会緑内障診療ガイドライン作成委員会 : 緑内障診療ガイドライン (第2版). 日眼会誌 110 (10) : 777-814, 2006

 

4) Ren R, Jonas JB, Tian G, et al : Cerebrospinal fluid pressure in glaucoma ; a prospective study. Ophthalmology 117 (2) : 259-266, 2010

PubMed

5) Michaelides, M, Kaines A, Hykin PG, et al : A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data : report 2. Ophthalmology 117 (6) : 1078-1086, 2010

 

6) 河原純子, 兵藤透, 馬場志郎, 他 : 血液透析患者における造影剤フルオレセイン造影後の透析の意義 : 1 透析症例を通じて. 透析会誌 44 (8) : 695-698, 2011

 

7) 大野敦, 梶邦成, 星加明乃, 他 : 糖尿病透析患者において眼科受診の中断・放置を防ぐ内科・眼科連携の試み. 透析会誌 41 (suppl 1) : 600, 2008

 

P.423 掲載の参考文献

1) 高森建二, 種田研一, 根木治 : 透析の痒み : その病態. Visual Dermatology 11 : 708-13, 2012

 

2) 段野貴一郎 : よくわかる透析患者のかゆみケア, 改訂2版, 金芳堂, 京都, 2005

 

3) 江畑俊哉 : かゆみの臨床的評価法. Progress in Medicine 27 : 1765-1768, 2007

Medical*Online

4) Kumagai H, Ebata T, Takamori K, et al : Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients : a Phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 25 : 1251-1257, 2010

PubMed

5) Kumagai H, Ebata T, Takamori K, et al : Efficacy and safety of a novel k-agonist for managing intractable pruritus in dialysis patients. Am J Nephrol 36 : 175-183, 2012

 

P.426 掲載の参考文献

1) 服部元史 : 成長障害. 腎と透析 72 (増刊号) : 133-136, 2012

 

2) Tonshoff B, Schaefer F, Mehls O : Disturbance of growth hormone-insulin-like growth factor axis in uraemia. Pediatr Nephrol 4 : 654-662, 1990

PubMed

3) 慢性腎臓病に対する食事療法基準 2007年版. 日腎会誌 49 : 871-878, 2007

 

4) 日本透析医学会 : 慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 透析会誌 45 : 301-356, 2012

 

5) 2008年版日本透析医学会「慢性腎臓病患者における腎性貧血治療のガイドライン」透析会誌 41 : 661-716, 2008

 

6) 日本臨床腎移植学会ガイドライン作成委員会編 : 腎移植後内科・小児科系合併症の診療ガイドライン, pp51-57, 日本医学館, 東京, 2011

 

7) Mehls O, Fine RN : Growth hormone treatment after renal transplantation : a promising but underused chance to improve growth. Pediatr Nephrol 28 (1) : 1-4, 2013

PubMed

P.430 掲載の参考文献

1) Braunstein GD : Clinical practice. Gynecomastia. N Engl J Med 357 (12) : 1229-1237, 2007

PubMed

2) Gikas P, Mokbel K : Management of gynaecomastia : an update. Int J Clini Prac 61 (7) : 1209-1215, 2007

 

3) Iglesias P, Carrero JJ, Diez JJ : Gonadal dysfunction in men with chronic kidney disease : clinical features, prognostic implications and therapeutic options. J Nephrol 25 (1) : 31-42, 2012

PubMed

4) Michalopoulos NV, Keshtgar MR : Images in clinical medicine. Gynecomastia induced by prostate-cancer treatment. N Engl J Med 367 (15) : 1449, 2012

PubMed

5) Eckman A, Dobs A : Drug-induced gynecomastia. Expert Opin Drug Saf 7 (6) : 691-702, 2008

PubMed

P.439 掲載の参考文献

1) Takei T, Otsubo S, et al : Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis. Nephron Clin Pract 108 : c278-c283, 2008

PubMed

2) Shigematsu T ; The Lanthanum Carbonate Research Group : Three-year extension study of lanthanum carbonate therapy in Japanese hemodialysis patients. Clin Exp Nephrol 14 (6) : 589-597, 2010

 

3) Raggi P, ChertowGM, et al : The ADVANCE study : a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 26 : 1327-1339, 2011

PubMed

4) 深川雅史編 : 慢性腎臓病に伴う骨ミネラル代謝異常 (CKD-MBD) : ガイドラインサポートハンドブック, pp330-331, 医薬ジャーナル社, 大阪, 2007

 

5) 青木明子, 安田雅子, 他 : 軟部組織巨大石灰化に対してエチドロネート長期投与が奏功するも, 病的骨折をきたした2透析例. 透析会誌 42 : 165-171, 2009

 

P.448 掲載の参考文献

1) 福西勇夫 : いらいら感. 腎と透析 53 (増刊号) : 429-430, 2002

 

2) 脇川健, 藤田淳也, 西平綾子 : 血液透析患者のレストレスレッグス症候群に対するプラミペキソールの臨床効果についての検討. 透析会誌 44 : 1155-1161, 2011

 

3) Roger SD, Harris DC, Stewart JH : Possible relation between restless legs and anaemia in renal dialysis patients. Lancet 337 : 1551, 1991

PubMed

4) Jaber BL, Schiller B, Burkart JM, et al : Impact of short daily hemodialysis on restless legs symptoms and sleep disturbances. Clin J Am Soc Nephrol 6 : 1049-1056, 2011

PubMed

5) Azar SA, Hatefi R, Talebi M : Evaluation of effect of renal transplantation in treatment of restless legs syndrome. Transplant Proc 39 : 1132-3, 2007

PubMed

6) Mucsi I, Molnar MZ, Ambrus C, et al : Restless legs syndrome, insomnia and quality of life in patients on maintenance dialysis. Nephrol Dial Transplant 20 : 571-7, 2005

PubMed

7) La Manna G, Pizza F, Persici E, et al : Restless legs syndrome enhances cardiovascular risk and mortality in patients with end-stage kidney disease undergoing long-term haemodialysis treatment. Nephrol Dial Transplant 26 : 1976-1983, 2011

PubMed

8) Unruh ML, Levey AS, D'Ambrosio C, et al : Restless legs symptoms among incident dialysis patients : association with lower quality of life and shorter survival. Am J Kidney Dis 43 : 900-909, 2004

PubMed

9) Walters AS : Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group. Mov Disord 10 : 634-642, 1995

 

10) Allen RP, Picchietti D, HeningWA, et al : Restless legs syndrome : diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 4 : 101-119, 2003

PubMed

11) Gigli GL, Adorati M, Dolso P, et al : Restless legs syndrome in end-stage renal disease. Sleep Med 5 : 309-315, 2004

PubMed

12) Kawauchi A, Inoue Y, Hashimoto T, et al : Restless legs syndrome in hemodialysis patients : health-related quality of life and laboratory data analysis. Clin Nephrol 66 : 440-446, 2006

PubMed

13) 黒岩義之, 平田幸一, 野村哲志, 他 : 標準的神経治療Restless legs症候群. 神経治療学 29 : 71-109, 2012

 

14) Paulus W, Dowling P, Rijsman R, et al : Pathophysiological concepts of restless legs syndrome. Mov Disord 22 : 1451-1456, 2007

PubMed

15) Garcia-Borreguero D, Stillman P, Benes H, et al : Algorithms for the diagnosis and treatment of restless legs syndrome in primary care. BMC Neurol 11 : 28, 2011

PubMed

16) 小池茂文, 坂名智, 岩田安世, 他 : 睡眠障害ケースカンファレンス (第20回) 末期慢性腎不全患者 (透析患者) の二次性レストレスレッグス症候群に合併した重症周期性四肢運動の一例 透析患者に対する薬物治療の注意点を含めて. 睡眠医療 5 : 459-467, 2012

 

17) 小池茂文 : 〔腎症の予防とケア〕診断 Questionレストレスレッグ症候群とは? Q&Aでわかる肥満と糖尿病 3 : 435-437, 2004

 

P.453 掲載の参考文献

1) American Psychiatric Association : Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text Revision (DSM-IV-TR), America Psychiatric Association, Washington, DC, 2000

 

2) 米国睡眠医学会 (日本睡眠学会診断分類委員会訳) : 睡眠障害国際分類 第2版-診断とコードの手引, 日本睡眠学会, 2005

 

3) 睡眠障害の診断・治療ガイドライン研究会, 内山真 (編) : 睡眠障害の対応と治療ガイドライン第2版, じほう, 東京, 2012

 

P.457 掲載の参考文献

1) 堀川直史 : 認知症の診断とマネジメント. 透析医会誌 25 : 178-182, 2010

 

2) 堀川直史 : 透析を受ける患者の心理とその特徴. 臨牀透析 34 : 1363-1368, 2008

 

3) 堀川直史 : 向精神薬の至適投与. 腎と透析 74 (3) : 415-420, 2013

Medical*Online

4) Levy, NB : Psychiatric considerations in the primary medical care of the patient with renal failure. Adv Ren Replace Ther 7 : 231-238, 2000

PubMed

5) 堀川直史 : 透析患者における認知症の薬物療法 : 主に周辺症状について. 透析医会誌 27 : 501-505, 2013

 

P.461 掲載の参考文献

1) 日本神経学会監修 : 認知症疾患治療ガイドライン 2010, 医学書院, 東京, 2010

 

2) Tamura MK, Yaffe K : Dementia and cognitive impairment in ESRD : diagnostic and therapeutic strategies. Kidney Int 79 : 14-22, 2011

 

3) Fukunishi I, Kitaoka T, Shirai T, Kino K, et al : Psychiatric disorders among patients undergoing hemodiaysis therapy. Nephron 91 : 344-347, 2002

 

4) 堀川直史 : 透析患者における認知症の薬物療法-主に周辺症状について-. 日透医会誌 27 (3) : 501-505, 2012

 

P.466 掲載の参考文献

1) 小林修三 : 透析患者の血圧管理 わが国のGLから. 腎と透析 69 : 279-282, 2010

Medical*Online

2) Port FK, et al : Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis 33 : 507-517, 1999

 

3) Zager PG, et al : "U" curve association of blood pressure and mortality in hemodialysis patients. Kidney Int 54 : 561-569, 1998

PubMed

4) Kalantar-Zadeh K, et al : Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 63 : 793-808, 2003

PubMed

5) Robinson BM, et al : Blood pressure levels and mortality risk among hemodialysis patients in the dialysis outcomes and practice patterns study. Kidney Int 82 : 570-580, 2012

PubMed

6) 小川哲也, 他 : 血圧管理におけるReverse epidemiology-介入試験, メタアナリシスから-. 腎と透析 69 : 265-268, 2010

Medical*Online

7) Heerspink HJ, et al : Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis : a systematic review and meta-analysis of randomized controlled trials. Lancet 373 : 1009-1015, 2009

PubMed

8) 鈴木洋通 : KDOQI, KDIGOのガイドラインから. 腎と透析 69 : 283-286, 2010

 

9) 日本透析医学会 : 血液透析患者における心血管合併症の評価と治療に関するガイドライン 第2章 血圧異常. 透析会誌 44 : 337-425, 2011

 

10) Foley RN, et al : Blood pressure and long-term mortality in United States hemodialysis patients : USRDS waves 3 and 4 study. Kidney Int 62 : 1784-1790, 2002

PubMed

11) 木村玄次郎 : ワンポイントノートで学ぶ透析療法の基本, 東京医学社, 東京, 2009

 

12) FukudaM, et al : Nocturnal blood pressure is elevated with natriuretics and proteinuria as renal function deteriorates in nephropathy. Kidney Int 65 : 621-625, 2004

 

13) Kimura G : Sodium, kidney and circadian rhythm of blood pressure. Clin Exp Nephrol 5 : 13-18, 2001

 

14) Moriya H, et al : Weekly averaged blood pressure is more important than a single-point blood pressure measurement in th risk stratification of dialysis patients. Clin J Am Soc Nephrol 3 : 416-422, 2007

 

15) Alborzi P, et al : Home blood pressures are of greater prognostic value than hemodialysis unit recordings. Clin J Am Soc Nephrol 2 : 1228-1234, 2007

PubMed

16) Tai DJ, et al : Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis : a meta-analysis. Clin J Am Soc Nephrol 5 : 623-630, 2010

PubMed

17) Nakao K, et al : b-blocker prescription and outcomes in hemodialysis patients from the Japan dialysis outcomes and practice patterns study. Nephron Clin Pract 113 : c132-c139, 2009

 

18) Cice G, et al : Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy : a prospective, placebocontrolled trial. J Am Coll Cardiol 41 : 1438-1444, 2003

 

19) Li Z, et al : The epidemiology of systolic blood pressure and death risk in hemodialysis patients. Am J Kidney Dis 48 : 606-615, 2006

PubMed

20) Stidley CA, et al. Changing relationship of blood pressure with mortality over time among hemodialysis patients. J Am Soc Nephrol 17 : 513-520, 2006

PubMed

P.469 掲載の参考文献

1) 日本透析医学会 : 血液透析患者における心血管合併症の評価と治療に関するガイドライン 第2章 血圧異常. 透析会誌 44 : 358-368, 2011

 

2) Shoji T, Tsubakihara Y, Fujii M, Imai E : Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int 66 : 1212-1220, 2004

PubMed

3) Khosla UM, Johnson RJ : Editorial : Hypertension in the hemodialysis patient and the "Lag Phenomenon" : Insights into pathophysiology and clinical management. Am J Kidney Dis 43 : 739-751, 2004

PubMed

4) K/DOQI Workgroup : K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 45 (4 suppl 3) : S1-153, 2005

 

P.474 掲載の参考文献

1) Lester SJ, Tajik AJ, Nishimura RA, et al : Unlocking the mysteries of diastolic function. J Am Coll Cardiol 51 : 679-689, 2008

PubMed

2) 平方秀樹, 新田孝作, 友雅司, 他 : 社団法人日本透析医学会 血液透析患者における心血管合併症の評価と治療に関するガイドライン. 透析会誌 44 : 337, 2011

 

P.476 掲載の参考文献

1) Alpert MA, Ravenscraft MD : Pericardial involvement in end-stage renal disease. Am J Med Sci 325 : 228-236, 2003

PubMed

2) Rutsky EA, Rostand SG : Treatment of uremic pericarditis and pericardial effusion. Am J Kidney Dis 10 : 2-8, 1987

PubMed

3) Schroeder JR, Osorno H, Chait R, Fischer A : Hiding in plain sight ; constrictive pericarditis. BMJ Case Rep 27 : 2013, 2013

 

4) Fuller TJ, Knochel JP, Brennan JP, Fetner CD, et al : Reversal of intractable uremic pericarditis by triamcinolone hexacetonide. Arch Intern Med 136 : 979-982, 1976

PubMed

P.480 掲載の参考文献

1) Bonow RO, Carabello BA, Chatterjee K, et al : 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 52 (13) : e1-142, 2008

 

2) Urena P, Malergue MC, Goldfarb B, Prieur P, et al : Evolution aortic stenosis in HD patients : analysis of risk factors. Nephrologie 20 : 217-225, 1999

 

3) London GM, Pannier B, Marchais SJ, Guerin AP : Calcification of the aortic valve in the dialysis patients. J Am Soc Nephrol 11 : 778-783, 2000

PubMed

4) Barreto DV, Barreto FC, Carvalho AB, et al : Coronary calcification in hemodialysis patients : the contribution of traditional and uremia-related risk factors. Kidney Int 67 : 1576-1582, 2005

 

5) Ishimura E, Okuno S, Kitatani K, et al : C-reactive protein is a significant predictor of vascular calcification of both aorta and hand arteries. Semin Nephrol 24 : 408-412, 2004

PubMed

6) Abbott KC, Agodoa LY : Hospitalizations for bacterial endocarditis after initiation of chronic dialysis in the United States. Nephron 91 : 203-209, 2002

PubMed

7) Rajamannan NM, Otto CM : Targeted therapy to prevent progression of calcific aortic stenosis. Circulation 110 : 1180-1182, 2004

PubMed

8) Osman L, Yacoub MH, Latif N, Amrani M et al : Role of human valve interstitial cells in valve calcification and their response to atrovastatin. Circulation 114 : I547-I552, 2006

 

9) Hung J, Chaput M, Guerrero JL, et al : Persistent reduction of ischemic mitral regurgitation by papillary muscle repositioning. Circulation 116 : I259-I263, 2007

PubMed

10) Nucifora G, Badano LP, Viale P, et al : Infective endocarditis in chronic haemodialysis patients : an increasing clinical challenge. Eur Heart J 28 : 2307-2312, 2007

PubMed

11) K/DOQI Workgroup : K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J KidneyDis 45 (suppl 3) : S1-S153, 2005

 

P.484 掲載の参考文献

1) Maron BJ, Towbin JA, Thiene G : Contemporary definitions and classification of the cardiomyopathies. Circulation 113 : 1807-1816, 2006.

PubMed

2) Mall G, Rambausek M, Neumeister A, et al : Myocardial interstitial fibrosis in experimental uremia-Implications for cardiac compliance. Kidney Int 33 : 804-811, 1988

PubMed

3) Raine AE, Seymour AML, Roberts AFC, et al : Impairment of cardiac function and energetics in experimental renal failure. J Clin Invest 92 : 2934-2940, 1993

 

4) Nishimura M, Murase M, Hashimoto T, et al : Insulin resistance and impaired myocardial fatty acid metabolism in dialysis patients with normal coronary arteries. Kidney Int 69 : 553-559, 2006

PubMed

5) 西村眞人, 迫田知佳子, 村川真悠子, 他 : 低血圧を有する長期透析患者の慢性心不全に対してピモベンダンが有効であった3症例. 新薬と治療 47 : 55-59, 2010

 

P.488 掲載の参考文献

1) 日本透析医学会 : 血液透析患者における心血管合併症の評価と治療に関するガイドライン. 透析会誌 44 (5) : 337-425, 2011

 

2) K/DOQI Working group : K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 45 (suppl 3) : S1-153, 2005

 

3) Herzog CA, Littrel K, Blaney M, et al : Clinical Characteristics of Dialysis Patients With Acute Myocardial Infarction in the United States. Circulation 116 : 1465-1472, 2007

 

4) Wanner C, Krane V, Ritz E, et al : Atrovastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 : 238-248, 2005

 

5) 急性冠症候群の診療に関するガイドライン. Circulation Journal 71 (suppl IV) : 2007

 

P.491 掲載の参考文献

1) Norgren L, Hiatt WR, Dormandy JA, et al : Intersociety consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 45 : S5-S67, 2007

 

2) O'Hare AM, et al : Renal insufficiency and the risk of lower extremity peripheral arterial disease : Results from the Heart and Estrogen/Progestin Replacement Study (HERS). J Am Soac Nephrol 15 : 1046-1051, 2004

 

3) 小林修三 : 糖尿病透析患者の下肢虚血への対応-早期発見と治療戦略-. 医学の歩み 240 (11) : 903-908, 2012

 

4) Rooke TW, Hirsch AT, Misra S, Sidawy AN, et al : 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline) : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 58 (19) : 2020-2045, 2011. doi : 10.1016/j. jacc. 2011.08.023. Epub 2011 Oct 6.

 

5) 日本循環器学会 : 循環器病の診断と治療に関するガイドライン末梢閉塞性動脈疾患の治療ガイドライン. Circ J 73 (suppl III) : 1507-1569, 2009

 

P.496 掲載の参考文献

1) 日本透析医学会 : 血液透析患者における心血管合併症の評価と治療に関するガイドライン. 透析会誌 44 (5) : 337-425, 2011

 

2) 脳卒中合同ガイドライン委員会 : 脳卒中治療ガイドライン 2009, 篠原幸人, 小川彰, 鈴木則宏, 他編, 協和企画, 東京, 2009

 

3) Power A, et al : High but stable incidence of subdural haematoma in haemodialysis- a single-centre study. Nephrol Dial Transplant 25 : 2272-2275, 2012

 

4) Sood P, et al : Subdural hematomas in chronic dialysis patients : significant and increasing. Clin J Am Soc Nephrol 2 : 956-959, 2007

PubMed

5) 重症頭部外傷治療・管理のガイドライン作成委員会 : 重症頭部外傷治療・管理のガイドライン 第2版. 日本神経外傷学会雑誌 29 : 1-115, 2006

 

P.502 掲載の参考文献

1) Onoyama K, Kumagai H, Miishima T, et al : Incidence of strokes and its prognosis in patients on maintenance hemodialysis. Jpn Heart J 27 : 685-691, 1986

PubMed

2) Ishida I, Hirakata H, Sugimori H, et al : Hemodialysis causes severe orthostatic reduction in cerebral blood flow velocity in diabetic patients. Am J Kidney Dis 34 : 1096-1104, 1999

PubMed

3) Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke 21 : 637-676, 1990

PubMed

4) Iguchi Y, Kimura K, Aoki J, et al : Prevalence of atrial fibrillation in community-dwelling Japanese aged 40 years or older in Japan : analysis of 41,436 nonemployee residents in Kurashiki-city. Circ J 72 : 909-913, 2008

PubMed

5) Inoue H, Fujiki A, Origasa H, et al : Prevalence of atrial fibrillation in the general population of Japan : an analysis based on periodic health examination. Int J Cardiol 137 : 102-107, 2009

PubMed

6) Wu CM, McLaughlin K, Lorenzetti DL, et al : Early risk of stroke after transient ischemic attack : a systematic review and meta-analysis. Arch Intern Med 167 : 2417-2422, 2007

PubMed

7) Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 : 71-86, 2002

PubMed

8) International Stroke Trial Collaborative Group : The International Stroke Trial (IST) : a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 349 : 1569-1581, 1997

PubMed

9) Saxena R, Lewis S, Berge E, et al : Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial. Stroke 32 : 2333-2337, 2001

PubMed

10) Paciaroni M, Agnelli G, Micheli S, et al : Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke : a meta-analysis of randomized controlled trials. Stroke 38 : 423-430, 2007

PubMed

11) Gubitz G, Sandercock P, Counsell C. Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev : CD000024, 2004

PubMed

12) van Walraven C, Hart RG, Singer DE, et al : Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation : an individual patient meta-analysis. JAMA 288 : 2441-2448, 2002

PubMed

13) 平方秀樹, 新田孝作, 友雅司, 他 : 血液透析患者における心血管合併症の評価と治療に関するガイドライン透析会誌 44 : 337-425, 2011

 

14) Kobayashi S, Tazaki Y : Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. Semin Thromb Hemost 23 : 531-534, 1997

PubMed

15) 豊田一則 : 維持透析患者の脳梗塞急性期治療-抗血栓療法の有効性. 血管医学 5 : 293-298, 2004

Medical*Online

16) Ethier J, Bragg-Gresham JL, Piera L, et al : Aspirin prescription and outcomes in hemodialysis patients : the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 50 : 602-611, 2007

 

17) Sandercock PA, Counsell C, Gubitz GJ, et al : Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev : CD000029, 2008

PubMed

18) 大友英一, 沓沢尚之, 小暮久也, 他 : 脳血栓症急性期におけるOKY-046の効果. 多施設二重盲検比較試験による用量設定試験 7 : 321-351, 1991

Medical*Online

19) CAPRIE Steering Committee : A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 : 1329-1339, 1996

 

20) Shinohara Y, Katayama Y, Uchiyama S, et al : Cilostazol for prevention of secondary stroke (CSPS 2) : an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 9 : 959-968, 2010

PubMed

21) The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group : Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 : 1581-1587, 1995

 

22) 日本脳卒中学会脳卒中医療向上・社会保険委員会rt-PA (アルテプラーゼ) 静注療法指針改訂部会 : rt-PA (アルテプラーゼ) 静注療法適正治療指針 (第二版), 2012

 

23) Naganuma M, Mori M, Nezu T, et al : Intravenous recombinant tissue plasminogen activator therapy for stroke patients receiving maintenance hemodialysis : the Stroke Acute Management with Urgent Risk-Factor Assessment and Improvement (SAMURAI) rt-PA registry. Eur Neurol 66 : 37-41, 2011

PubMed

24) Palacio S, Gonzales NR, Sangha NS, et al : Thrombolysis for acute stroke in hemodialysis : international survey of expert opinion. Clin J Am Soc Nephrol 6 : 1089-1093, 2011

PubMed

25) Bath P, Chalmers J, Powers W, et al : International Society of Hypertension (ISH) : statement on the management of blood pressure in acute stroke. J Hypertens 21 : 665-672, 2003

PubMed

26) Irie K, Yamaguchi T, Minematsu K, et al : The Jcurve phenomenon in stroke recurrence. Stroke 24 : 1844-1849, 1993

PubMed

27) Hansson L, Zanchetti A, Carruthers SG, et al : Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension : principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351 : 1755-1762, 1998

 

28) Arima H, Chalmers J, Woodward M, et al : Lower target blood pressures are safe and effective for the prevention of recurrent stroke : the PROGRESS trial. J Hypertens 24 : 1201-1208, 2006

 

29) Righetti E, Celani MG, Cantisani T, et al : Glycerol for acute stroke. Cochrane Database Syst Rev : CD000096, 2004

PubMed

30) Aguilar MI, Hart R, Pearce LA : Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev : CD006186, 2007

PubMed

31) Gage BF, Waterman AD, Shannon W, et al : Validation of clinical classification schemes for predicting stroke : results from the National Registry of Atrial Fibrillation. JAMA 285 : 2864-2870, 2001

 

32) Winkelmayer WC, Patrick AR, Liu J, et al : The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol 22 : 349-357, 2011

PubMed

33) Yang F, Chou D, Schweitzer P, et al : Warfarin in haemodialysis patients with atrial fibrillation : what benefit? Europace 12 : 1666-1672, 2010

PubMed

34) Abe S, Yoshizawa M, Nakanishi N, et al : Electrocardiographic abnormalities in patients receiving hemodialysis. Am Heart J 131 : 1137-1144, 1996

PubMed

35) Abbott KC, Trespalacios FC, Taylor AJ, et al : Atrial fibrillation in chronic dialysis patients in the United States : risk factors for hospitalization and mortality. BMC Nephrol 4 : 1, 2003

PubMed

36) Chan KE, Lazarus JM, Thadhani R, et al : Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 20 : 2223-2233, 2009

PubMed

37) Wizemann V, Tong L, Satayathum S, et al : Atrial fibrillation in hemodialysis patients : clinical features and associations with anticoagulant therapy. Kidney Int 77 : 1098-1106, 2010

PubMed

38) Winkelmayer WC, Liu J, Setoguchi S, et al : Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol 6 : 2662-2668, 2011

PubMed

39) Sood MM, Komenda P, Sood AR, et al : The intersection of risk and benefit : is warfarin anticoagulation suitable for atrial fibrillation in patients on hemodialysis? Chest 136 : 1128-1133, 2009

PubMed

40) Zimmerman D, SoodMM, Rigatto C, et al : Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant 27 : 3816-3822, 2012

PubMed

P.507 掲載の参考文献

1) Johnston SC, Gress DR, Browner WS, et al : Short-term prognosis after emergency department diagnosis of TIA. JAMA 284 : 2901-2906, 2000

PubMed

2) Wu CM, McLaughlin K, Lorenzetti DL, et al : Early risk of stroke after transient ischemic attack : a systematic review and meta-analysis. Arch Intern Med 167 : 2417-2422, 2007

PubMed

3) 日本脳卒中学会 : 脳卒中治療ガイドライン 2009. http://www.jsts.gr.jp/jss08.html

 

4) Johnston SC, Rothwell PM, Nguyen-Huynh MN, et al : Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 369 : 283-292, 2007

PubMed

5) Ethier J, Bragg-Gresham JL, Piera L, et al : Aspirin prescription and outcomes in hemodialysis patients : the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 50 : 602-611, 2007

 

P.510 掲載の参考文献

1) Elion GB, Furman PA, Fyfe JA, et al : The selectivity of action of an antiherpetic agent, 9- (2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci USA 74 : 5716-5720, 1977

 

2) Elion GB, Furman PA, Fyfe JA, et al : The selectivity of an antiherpetic agent, 9- (2-hydroxyethoxymethyl) guanine. Rev Med Virol 9 (3) : 147-153, 1999

PubMed

3) 天保英明, 他 : 薬剤性脳症の患者ケア. 透析ケア 8 (11) : 1098-1103, 2002

 

4) 窪田実 : 薬物中毒と血液浄化法, アシクロビル. 臨牀透析 18 (8) : 1071-1074, 2002

 

5) Tokinaga N : Hallucinations after a therapeutic dose of benzodiazepine hypnotics with co-administrations of erythromycin. Psychiatry Clin Neurosci 50 : 337-339, 1996

PubMed

P.514 掲載の参考文献

1) 伊藤和郎 : 各種病態の合併症としての出血性消化器疾患 尿毒症. 日本臨牀 56 (9) : 2391-2395, 1998

 

2) 蜂巣忠, 吉田豊彦 : 腎疾患と消化管病変. 臨牀消化器内科 5 (12) : 1815-1821, 1990

 

3) 高橋寛 : 腎臓症候群-上部消化管合併症. 日本臨牀領域別症候群シリーズ 17 : 39-41, 1997

 

4) 日本腎臓学会編 : CKD診療ガイド 2012, 東京医学社, 東京, 2012

 

5) 伊藤和郎 : 維持透析患者のHelicobacter Pylori除菌. 臨牀透析 8 : 1161-1166, 2006

 

6) 徳島秀次, 井上満佐也, 他 : 慢性腎不全におけるHelicobacter Pylori感染による上部消化管病変と治療の実際. 消化器の臨牀 3 : 354-359, 2003

 

P.518 掲載の参考文献

1) 日本消化器病学会編 : 胆石症診療ガイドライン, 南江堂, 東京, 2009

 

2) Ishiguro S, Inoue M, Kurahashi N, et al : Risk factors of biliary tract cancer in a large-scale population-based cohort study in Japan (JPHC study) ; with special focus on cholelithiasis, body mass index, and their effect modification. Cancer Causes Control 19 (1) : 33-41, 2008

 

3) Attili AF, De Santis A, Capri R, et al : The natural history of gallstones : the GREPCO experience. The GREPCO Group. Hepatology 21 (3) : 655-660, 1995

PubMed

4) Fendrick AM, Gleeson SP, Cabana MD, et al : Asymptomatic gallstones revisited. Is there a role for laparoscopic cholecystectomy? Arch Fam Med 2 (9) : 959-968, 1993

 

5) 平田純生, 和泉智, 古久保拓, 他 : 透析患者への投薬ガイドブック改訂2版, じほう, 東京, 2009

 

P.522 掲載の参考文献

1) Aiken JJ, Oldham KT : Acute Appendicitis. Nelson Textbook of Pediatrics, 19th ed, Kliegman RM, Stanton BF, Geme JW, et al (eds), pp1349-1355, Saunders/Elsevier, Philadelphia, 2011

 

2) Miura S, et al : Recent trends in diverticulosis of the right colon in japan : retrospective review in a regional hospital. Dis colon Rectum 43 : 1383-1389, 2000

 

3) Strate LL, et al : Use of aspirin or nonsteroidal antiinflammatory drugs increases risk for divertuculitis and diverticular bleeding. Gastroenterology 140 : 1427-1433, 2011

 

4) 田辺聡, 他 : 内視鏡的止血ガイドライン. 消化器内視鏡ガイドライン (第3版), 日本消化器内視鏡学会卒後教育委員会 (編), pp188-205, 医学書院, 東京, 2006

 

5) Olesen M, Eriksson S, Bohr J, et al : Microscopic colitis : a common diarrhoeal disease. An epidemiological study in Orebro, Sweden, 1993-1998. Gut 53 : 346-350, 2004

PubMed

6) Beaugerie L, Pardi DS : Review article : drug-induced microscopic colitis-proposal for a scoring system and review of the literature. Aliment Pharmacol Ther 22 : 277-284, 2005

PubMed

P.533 掲載の参考文献

1) 急性膵炎診療ガイドライン 2010 改訂出版委員会 : 急性膵炎診療ガイドライン 2010 [第3版]. 高田忠敬編. 金原出版, 東京, 2010

 

2) 厚生労働省難治性膵疾患に関する調査研究班, 日本膵臓学会, 日本消化器病学会 : 下瀬川徹, 神澤輝実, 他 : 慢性膵炎臨床診断基準 2009. 膵臓 24 : 645-708, 2009

 

3) 厚生労働省難治性膵疾患調査研究班・日本膵臓学会 : 岡崎和一, 川茂幸, 神澤輝実編集, 下瀬川徹, 田中雅夫監修 : 自己免疫性膵炎診療ガイドライン 2009. 膵臓 24 Suppl : 1-54, 2009

 

4) 日本膵臓学会・厚生労働省難治性膵疾患に関する調査研究班 : 岡崎和一, 下瀬川徹, 他 : 自己免疫性膵炎臨床診断基準 2011. 膵臓 27 : 17-25, 2012

 

5) 浦部晶夫, 島田和幸, 川合眞一編 : 今日の治療薬解説と便覧 2012, 南江堂, 東京, 2012

 

6) 厚生労働科学研究費補助金難治性疾患等克服研究事業 (難治性疾患克服研究事業) 難治性膵疾患に関する調査研究平成24年度総括・分担研究報告書. 研究代表者下瀬川徹, 仙台, 2013

 

P.536 掲載の参考文献

1) Boley SJ, Schwartz S, Lash J, et al : Reversible vascular occlusion of the colon. Surg Gynecol Obstet 116 : 53-60, 1963

PubMed

2) Marston A, Pheils MT, Thomas ML, et al : Ischaemic colitis. Gut 7 (1) : 1-15, 1966

PubMed

3) 吉田豊, 棟方昭博, 中路重之 : 〔虚血性大腸炎〕虚血性大腸炎の疫学. 臨床消化器内科 3 (8) : 1109-1114, 1988

 

4) 戸澤勝之, 上小鶴孝二, 川浩介, 他 : 〔消化管疾患における性差医学性差の視点に立った研究と診療〕虚血性腸炎と性差. GI Research 15 (1) : 43-47, 2007

 

5) 飯田三雄, 松本主之, 広田千治, 他 : 虚血性腸病変の臨床像虚血性大腸炎の再評価と問題点を中心に. 胃と腸 28 (9) : 889-912, 1993

 

6) 大川清孝, 佃博, 青木哲哉, 他 : 虚血性大腸炎急性期の内視鏡像の検討. Gastroenterological Endoscopy 46 (7) : 1323-1332, 2004

 

P.539 掲載の参考文献

1) 清水誠治 : 〔内科 疾患インストラクションガイド 何をどう説明するか〕消化器疾患偽膜性大腸炎・抗生物質関連腸炎. Medicina 48 (11) : 230-233, 2011

 

2) Stoddart B, Wilcox MH : Clostridium difficile. Curr Opin Infect Dis 15 (5) : 513-518, 2002

PubMed

3) 齋藤充生 : 重篤副作用疾患別対応マニュアルおよび抗生物質・抗菌薬が関与する重篤副作用について. Jpn J Antibiot 61 (4) : 269-288, 2008

 

4) 飯田三雄, 松本主之, 広田千治, 他 : 虚血性腸病変の臨床像虚血性大腸炎の再評価と問題点を中心に. 胃と腸 28 (9) : 889-912, 1993

 

5) 平田純生, 和泉智, 古久保拓編 : 透析患者への投薬ガイドブック, p581, じほう, 東京, 2009

 

P.548 掲載の参考文献

1) Yen-Hsuan Ni : Natural history of chronic hepatitis B virus infection : pediatric perspective. J Gastroenterol 46 : 1-8, 2011

PubMed

2) 秋葉隆 : 透析患者のウィルス肝炎-歴史とその撲滅の意義-. 臨牀透析 25 : 1253-1258, 2009

 

3) 佐藤千史, 石川博子, 宮川八平 : 透析患者のウィルス肝炎の現状と予後への影響. 臨牀透析 25 : 1259-1266, 2009

 

4) 原田孝司, 李嘉明, 船越哲 : 透析患者のウィルス肝炎の診断 (1). サーベイランス 25 : 1267-1274, 2009

 

5) 平成19年度厚生労働省科学研究費補助金 (肝炎等克服緊急対策研究事業) 透析医療における標準的な透析操作と院内感染予防に関するマニュアル (三訂版), 2008

 

6) Kobayashi M, Ikeda K, Arase Y, et al : Change of hepatitis B virus genotypes in acute and chronic infection in Japan. J. Med. Virol. 80 : 1880-1884, 2008

PubMed

7) 山田典栄, 他 : 首都圏におけるB型急性肝炎の実態と変遷. 肝臓 49 (12) : 553-559, 2008

 

8) Aspinall EJ et al : Hepatitis B prevention, diagnosis, treatment and care : a review. OccupMed (Lond). 61 : 531-540, 2011

 

9) 日本透析医学会 : 透析患者のC型ウィルス肝炎治療ガイドライン. 透析会誌 44 : 481-531, 2011

 

10) 熊田博光, 他 : 厚生労働省科学研究班, 平成23年度報告書, 平成24年3月

 

P.552 掲載の参考文献

1) Kidney Disease : Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int 73 (suppl 109) : S1-S99, 2008

 

2) Uhlig K, MacLeod A, Craig J, Lau J, et al : Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease : Improving Global Outcomes (KDIGO). Kidney Int 70 : 2058-2065, 2006

PubMed

3) 深川雅史, 塚本雄介, 椿原美治, 海津嘉蔵, 他 : エビデンスレベル評価とガイドライン推奨度について. 透析会誌 43 : 347-349, 2010

 

4) 秋葉隆, 洞和彦, 井廻道夫, 佐藤千史, 他 : 透析患者のC型ウイルス肝炎治療ガイドライン. 透析会誌 44 : 481-531, 2011

 

5) 平成23年度厚生労働省厚生科学研究費肝炎等克服緊急対策研究事業 (肝炎分野) ウイルス性肝炎における最新の治療法の標準化を目指す研究班による平成24年B型C型慢性肝炎・肝硬変治療のガイドライン

 

P.555 掲載の参考文献

1) 細菌性髄膜炎の治療ガイドライン作成委員会 (糸山泰人, 他) : 細菌性髄膜炎の治療ガイドライン. 神経治療学 24 : 71-132, 2007

 

2) de Gans J, van de Beek D ; European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators : Dexamethasone in adults with bacterial meningitis. N Engl J Med 347 : 1549-1556, 2002

 

3) Peterkovic V, Trkulja V, Kutlesa M, et al : Dexamethasone for adult community-acquired bacterial meningitis : 20 years of experience in daily practice. J Neurol 259 : 225-236, 2012

PubMed

4) Thwaites G, Fisher M, Hemingway C, et al : British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect 59 : 167-187, 2009

 

5) Prasad K, Singh MB : Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev 2008 Jan 23

 

P.558 掲載の参考文献

1) Allon M, Depner TA, Radeva M, Bailey J, et al : HEMO Study Group : Impact of dialysis dose and membrane on infection-related hospitalization and death : results of the HEMO Study. J Am Soc Nephrol 14 (7) : 1863-1870, 2003

 

2) 日本透析医学会 : 図説わが国の慢性透析療法の現況 2011年12月31日現在, 2012

 

3) United States Department of Health and Human services, USRDS 2012 Annual Data Report http://www.usrds.org/adr.aspx

 

4) Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. American Journal of Respiratory and Critical Care Medicine 171 : 388-416, 2005

PubMed

5) 医療・介護関連肺炎 (NHCAP) 診療ガイドライン作成委員会 : 医療・介護関連肺炎診療ガイドライン, 日本呼吸器学会, 2011

 

6) Viasus D, Garcia-Vidal C, Cruzado JM, Adamuz J, et al : Epidemiology, clinical features and outcomes of pneumonia in patientswith chronic kidney disease. Nephrol Dial Transplant 26 : 2899-2906, 2011

 

7) Slinin Y, Foley RN, Collins AJ : Clinical epidemiology of pneumonia in hemodialysis patients : the USRDS waves 1, 3, and 4 study. Kidney Int 70 : 1135-1141, 2006

 

8) Kawasaki S, Aoki N, Kikuchi H, Nakayama H, et al : Clinical and microbiological evaluation of hemodialysis-associated pneumonia (HDAP) : should HDAP be included in healthcare-associated pneumonia? J Infect Chemother 17 (5) : 640-645, 2011

PubMed

9) 日本化学療法学会, 日本TDM学会 : 抗菌薬TDMガイドライン, 2012

Medical*Online

10) Rangel MC, Coronado VG, Euler GL, Strikas RA : Vaccine recommendations for patients on chronic dialysis. The Advisory Committee on Immunization Practices and the American Academy of Pediatrics. Semin Dial 13 (2) : 101-107, 2000

 

P.562 掲載の参考文献

1) 金城福則, 金城渚, 仲本学, 岸本一人, 他 : IBDと紛らわしい腸管感染症 ; 鑑別法を中心に. IBD Research 3 (2) : 115-122, 2009

Medical*Online

2) 斉藤裕輔, 垂石正樹, 鈴木聡, 助川龍士, 他 : 感染性腸炎の診断・治療手順. 胃と腸 43 (11) : 1573-1580, 2008

 

3) 猿田雅之, 田尻久雄 : 院内で発症した下痢・便秘への対応. レジデント 4 (11) : 37-48, 2011

 

4) 柳秀高 : 感染性下痢で抗菌薬投与はどのような場合に必要か? medicina 43 (13) : 2006-2007, 2006

 

5) 日本腎臓学会編 : CKD診療ガイド 2012. 日腎会誌 54 (8) : 1031-1189, 2012

 

P.566 掲載の参考文献

1) 臨床透析ハンドブック 第4版, Daugirdas JT, Blake PG, Ing TS編, pp505-508, メディカル・サイエンス・インターナショナル, 東京, 2009

 

2) Fasolo LR, Rocha LM, Campbell S, et al : Diagnostic relevance of pyuria in dialysis patients. Kidney Int 70 : 2035-2038, 2006.

PubMed

3) Mortazavi M, Seyrafian S, Shahidi S, et al : Pyuria as a screening test for detection of urinary tract infection in patients on long-term hemodialysis. IJKD 5 : 50-52, 2011

PubMed

4) 高橋聡 : 単純性尿路感染症. 泌尿器科感染症外来 第1版, 吉田修監修, 塚本泰司編, pp24-29, メジカルビュー社, 東京, 2003

 

5) Vij R, Nataraj S, Peixoto AJ : Diadnostic utility of urinalysis in detecting urinary tract infection in hemodialysis patients. Nephron Clin Pract 113 : 281-285, 2009

 

6) 渡辺浩志, 川西秀樹 : 泌尿器感染症. 腎と透析 53 (増刊号) : 512-514, 2002

 

7) Bonal J, Caralps A, Lauzurica R, et al : Cyst infection in acquired renal cystic disease. British Med Journal 295 : 25, 1987

 

8) 荒川創一 : 泌尿器科感染症. 抗菌薬使用のガイドライン 第1版, 日本感染症学会日本化学療法学会編, pp186-192, 協和企画, 東京, 2006

 

9) 病原微生物に対する薬剤. 腎機能低下時の薬剤ポケットマニュアル 第2版, 南学正臣編, pp2-32, 中外医学社, 東京, 2011

 

P.569 掲載の参考文献

1) 日本透析医学会編 : 慢性血液透析用バスキュラーアクセスの作製および修復に関するガイドライン. 透析会誌 44 (9) : 855-937, 2011

 

2) 平中俊行, 中村順一, 中山祐治 : 人工血管内シャントの感染と対策. 腎と透析59別冊アクセス 2005 : 24-26, 2005

 

3) Bhutta A, Gilliam C, Honeycutt M, Schexnayder S, et al : Reduction of bloodstream infections associated with catheters in paediatric intensive care unit : stepwise approach. BMJ 334 (7589) : 362-365, 2007

PubMed

4) Parker MG, Doebbeling BN : The challenge of methicillin-resistant Staphylococcus aureus prevention in hemodialysis therapy. Semin Dial 25 (1) : 42-49, 2012

PubMed

P.574 掲載の参考文献

1) Li PK, Szeto CC, Piraino B, et al : Peritoneal dialysisrelated infections recommendations : 2010 update. Perit Dial Int 30 : 393-423, 2010

PubMed

2) 小児PD研究会 : 小児PD治療マニュアル, http://www.linkclub.or.jp/-pedpdjpn/

 

3) Warady BA, Scfaefer F, Holloway M, et al : Consensus guidelines for the treatment of peritonitis in pediatric patients receiving peritoneal dialysis. Perit Dial Int 20 : 610-624, 2000

 

4) Wiggins KJ, Craig JC, Johnson DW, et al : Treatment for peritoneal dialysis-associated peritonitis. The Cochrane Library 4 : 2010

 

P.578 掲載の参考文献

1) Surviving Sepsis Campaign : International Guidelines for Management of Severe Sepsis and Septic Shock : 2012. Critical Care Medicine 41 : 580-637, 2013

PubMed

2) 日本集中治療医学会Sepsis Registry委員会 : 日本版 敗血症診療ガイドライン. 日集中医誌 20 : 124-173, 2013

 

3) 栗原陽子, 人見重美 : 敗血症. Medical Practice 28 (臨時増刊号) : 346-351, 2011

 

4) 日本透析医学会統計調査委員会 : わが国の慢性透析療法の現況 (2011年12月31日現在). 透析会誌 46 : 1-76, 2013

 

5) 岩渕仁, 他 : 血液透析患者に発生した敗血症についての検討. 透析会誌 44 (7) : 617-622, 2011

 

6) 日本腎臓学会編 : CKD診療ガイド 2012. 日腎会誌 54 (8) : 1031-1189, 2012

 

P.583 掲載の参考文献

1) 日本透析医学会統計調査委員会 : 図説 わが国の慢性透析療法の現況2011年12月31日現在

 

2) WakasugiM, Kawamura K, et al : High Mortality Rate of Infectious Diseases in Dialysis Patients : A Comparison With the General Population in Japan. Ther Apher Dial 16 : 226-231, 2012

PubMed

3) Asai A, Tsuda Y et al : Pathogenic Role of Macrophages in Intradermal Infection of Methicillin-Resistant Staphylococcus aureus in Thermally Injured Mice. Infect Immun 78 : 4311-4319, 2010

PubMed

4) Mohr JF, Murray BE : Point : Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 44 : 1536-1542, 2007

 

5) Patel N, Pai MP et al : Vancomycin : we can't get there from here. Clin Infect Dis 52 : 969-974, 2011

 

P.587 掲載の参考文献

1) 日本腎臓病薬物療法学会 : 腎機能低下時に最も注意必要な薬剤投与量一覧. http://jsnp.kenkyuukai.jp/information/

 

2) 磯貝和也, 杉山健太郎, 高橋公太 : 血液透析患者へのバルガンシクロビルの投与例設定に薬剤師が関与した一症例. 医薬ジャーナル 48 (6) : 1541-1546, 2012

 

3) 本田まり子 : 透析患者の抗ヘルペスウイルス療法の実際. 日透医会誌 25 (2) : 246-252, 2010

 

4) Darville JM, Lovering AM, MacGowan AP : Development, evaluation and application of an isocratic highperformance liquid chromatography (HPLC) assay for the simultaneous determination of aciclovir and its metabolite 9-carboxymethoxymethylguanine in human serum and cerebrospinal fluid. Int J Antimicrob Agents 30 (1) : 30-33, 2007

PubMed

P.592 掲載の参考文献

1) 日本透析医会と日本透析医学会新型インフルエンザ対策合同会議 : 透析施設におけるインフルエンザ対策ガイドライン (http://www.ouseki-ikai.or.jp/htm/07_manual/doc/20081208_influenza.pdf)

 

2) 社団法人日本感染症学会提言 2012-インフルエンザ病院内感染対策の考え方について- (高齢者施設を含めて) 日本感染症学会, (http://www.kansensho.or.jp/influenza/pdf/1208_teigen.pdf) (2012年8月20日)

 

3) 日本感染症学会新型インフルエンザ対策委員会 : 日本感染症学会提言 2010-01-25 -新規薬剤を含めた抗インフルエンザ薬の使用適応について- 日本感染症学会, (http://www.kansensho.or.jp/topics/pdf/100122soiv_teigen.pdf) (2010年1月25日).

 

4) 大田敏之 : 本邦小児に頻用される薬物の腎機能低下時の投与量, 投与法. 小児腎臓病学, 日本小児腎臓病学会編, pp445-452, 診断と治療社, 東京, 2012

 

5) 日本感染症学会 : 新型インフルエンザ診療ガイドライン (第1版), 日本感染症学会, (http://www.kansensho.or.jp/) (2009年9月15日)

 

P.597 掲載の参考文献

1) 日本透析医会・日本透析医学会HIV感染患者透析医療ガイドライン策定グループ : HIV感染患者透析医療ガイドライン, 2010

 

2) HIV感染症治療研究会 : HIV感染症治療の手引き 第16版, 2012

 

3) 平成23年度厚生労働科学研究費補助金エイズ対策研究事業「HIV感染症及びその合併症の課題を克服する研究班」 : 抗HIV治療ガイドライン, 2013

 

4) Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents : Feb 17, 2013 (http://aidsinfo.nih.gov/)

 

P.601 掲載の参考文献

1) Yu VL, et al : An International prospective study of pneumococcal bacteremia : correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 37 : 230-237, 2003

PubMed

2) Ben-Ami R, et al : A multinational survey of risk factors for infection with extended-spectrum blactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 42 (7) : 925-934, 2006

 

3) Tateda K : 109th Scientific Meeting of the Japanese Society of Internal Medicine : symposium : 3. Infectious diseases--recent trend and future issues ; 2) Multiple antibiotic resistant Gram-negative bacterial infections. Nihon Naika Gakkai Zasshi 101 (9) : 2591-2598, 2012

PubMed

4) Garnacho-Montero J, et al : Multiresistant Acinetobacter baumannii infections : epidemiology and management. Curr Opin Infect Dis 23 : 332-339, 2010

PubMed

P.604 掲載の参考文献

1) 加藤真史, 絹川常朗 : 結核. 腎移植・血管外科 21 (2) : 137-141, 2009

 

2) 今田聰雄 : 透析医療と感染症. 治療 84 : 1589-1593, 2002

Medical*Online

3) 中山均, 桜林耐, 宮崎滋, 他 : 透析患者の呼吸器合併症 VI 肺結核. 臨牀透析 22 : 151-158, 2006

 

4) 青池郁夫, 鈴木正司, 薄田芳丸 : 結核症の診断法. 臨牀透析 22 : 151-158, 2006

 

5) 山川智之 : 透析患者の合併症とその対策結核. 日透医会誌 19 : 33-43, 2010

 

6) 田中章郎, 平田純生 : 透析医療に必要な薬の使用方法・注意点一覧表. 腎と透析 70 (4) : 685-715, 2011

Medical*Online

7) WHO : Treatment of tuberculosis GUIDELINES Fourth edition, WHO/HTM/TB/2009. 420

 

P.608 掲載の参考文献

1) Kuo CC, Lee CT, Lee IM, et al : Risk of herpes zoster in patients treated with long-term hemodialysis : a matched cohort study. Am J Kidney Dis 59 (3) : 428-433, 2012

PubMed

2) 大塚藤男 : 皮膚感染症 (帯状疱疹を中心に). 腎と透析 53 (臨時増刊号) : 546-548, 2002

 

3) 古久保拓, 平田純生, 太田美由希, 他 : 血液透析患者の帯状疱疹に対する塩酸バラシクロビルの適正投与法に関する検討. 医療薬学 30 (8) : 547-552, 2004

Medical*Online

4) 東川竜也, 古久保拓, 佐藤みのり, 他 : 透析患者におけるアシクロビル代謝物CMMGのアシクロビル脳症への関与. 医療薬学 33 (7) : 585-590, 2007

Medical*Online

5) Laskin OL, Longstreth JA, Whelton A, et al : Effect of renal failure on the pharmacokinetics of acyclovir. Am J Med 73 : 197-201, 1982

PubMed

P.613 掲載の参考文献

1) Ricks J, Molnar MZ, Kovesdy CP, et al : Glycemic control and cardiovascular mortality in hemodialysis patients with diabetes : a 6-year cohort study. Diabetes 61 : 708-715, 2012

PubMed

2) Inaba M, Okuno S, Kumeda Y, et al : Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes : effect of anemia and erythropoietin injection. J Am Soc Nephrol 18 : 896-903, 2007

PubMed

3) 森克仁, 絵本正憲 : 糖尿病腎不全に血糖コントロールは必要か? (第3回) 治療戦略を考える. プラクティス 28 : 235-238, 2011

Medical*Online

4) Abe M, Okada K, Soma M : Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis : metabolism and clinical practice. Curr Drug Metab 12 : 57-69, 2011

PubMed

5) Hasslacher C : Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 23 : 886-891, 2003

 

P.618 掲載の参考文献

1) 日本透析医学会統計調査委員会 : 図説わが国の慢性透析療法の現況 (2011年12月31日現在), 2012

 

2) Shoji T, et al : Chronic kidney disease, dyslipidemia, and atherosclerosis. J Atheroscler Thromb 19 : 299-315, 2012

 

3) 日本動脈硬化学会編 : 動脈硬化性疾患予防ガイドライン 2012年度版, 2012

 

4) 日本透析医学会 : 血液透析患者における心血管合併症の評価と治療に関するガイドライン. 透析会誌 44 : 337-425, 2011

 

5) Baigent C, et al : The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection) : a randomised placebo-controlled trial. Lancet 377 : 2181-2192, 2011

PubMed

6) Wanner C, et al : Atorvastatin in patients with type2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 : 238-248, 2005

 

7) 日本腎臓学会編 : CKD診療ガイド 2012, 東京医学社, 東京, 2012

 

P.625 掲載の参考文献

1) Stenvinkel P, Heimburger O, Paultre F, et al : Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55 : 1899-1911, 1999

PubMed

2) 中井滋, 渡邊有三, 政金生人, 他 : わが国の慢性透析療法の現況 (2011年12月31日現在). 透析会誌 46 : 1-76, 2013

 

3) Tsubakihara Y, Takabatake Y, Oka K, et al : Effects of the oral adsorbent AST-120 on tryptophan metabolism in uremic patients. Am J Kidney Dis 41 (suppl 1) : S38-41, 2003

 

4) Stratton RJ, Bircher G, Fouque D, et al : Multinutrient oral supplements and tube feeding in maintenance dialysis : a systematic review and meta-analysis. Am J Kidney Dis 46 : 387, 2005

PubMed

5) Hiroshige K, Iwamoto M, Kabashima N, et al : Prolonged use of intradialysis parenteral nutrition in elderly malnourished chronic haemodialysis patients. Nephrol Dial Transplant 13 : 2081-2087, 1998

PubMed

P.629 掲載の参考文献

1) Brewster UC, Perazella MA : Intravenous iron and the risk of infection in end-stage renal disease patients. Semin Dial 17 (1) : 57-60, 2004

PubMed

2) Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, et al : Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106 (17) : 2212-2217, 2002

PubMed

3) 小澤敬也 : 輸血後鉄過剰症の診療ガイド. 厚生労働科学研究補助金難治性疾患克服研究事業 : 特発性造血障害に関する調査報告 (平成20年度版)

 

4) Nakanishi T, Kuragano T, Nanami M, Otaki Y, et al : Importance of ferritin for optimizing anemia therapy in chronic kidney disease. Am J Nephrol 32 (5) : 439-446, 2010

PubMed

5) Canavese C, Bergamo D, Ciccone G, Longo F, et al : Validation of serum ferritin values by magnetic susceptometory in predicting iron overload in dialysis patients. Kidney Int 65 : 1091-1098, 2004

PubMed

6) Rostoker G, Griuncelli M, Loridon C, Couprie R, et al : Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents : a MRI study. Am J Med 125 (10) : 991-999, 2012

PubMed

7) 福井真二, 鳥本一匡, 影林頼明, 森本勝彦, 他 : 慢性腎不全・骨髄異形成症候群合併症例における鉄過剰症に対する経口鉄キレート剤の効果と安全性. 透析会誌 42 (11) : 865-869, 2009

 

8) 安田圭子, 佐々木公一, 玉置俊治, 林晃正, 他 : 血液透析導入した鉄過剰合併骨髄不全症候群患者の1例. 腎と透析 72 : 405-408, 2012

 

9) Kuragano T, Shimonaka Y, Kida A, Furuta M, et al : Determinants of hepcidin in patients on maintenance hemodialysis : role of inflammation. Am J Nephrol 31 (6) : 534-540, 2010

 

P.634 掲載の参考文献

1) Matsuo K, Ikizler TA, Hoover RL, NakamotoM, et al : Transforming growth factor-beta is involved in the pathogenesis of dialysis-related amyloidosis. Kidney Int 57 : 697-708, 2000

PubMed

2) Menaa C, Esser E, Sprague SM : Beta 2-microglobulin stimulates osteoclast formation. Kidney Int 73 : 1275-1281, 2008

PubMed

3) Gejyo F, Narita I : Current clinical and pathogenetic understanding of beta 2-m amyloidosis in long-term haemodialysis patients. Nephrology (Carlton) 8 (suppl) : S45-49, 2003

 

4) Cruz DN, de Cal M, Ronco C : Oxidative stress and anemia in chronic hemodialysis : The promise of bioreactive membranes. Contrib Nephrol 161 : 89-98, 2008

PubMed

5) Nakai S, Iseki K, Itami N, Ogata S, et al : An overview of regular dialysis treatment in japan (as of 31 december 2010). Ther Apher Dial 16 : 483-521, 2012

PubMed

6) Warren DJ, Otieno LS : Carpal tunnel syndrome in patients on intermittent haemodialysis. Postgrad Med J 51 : 450-452, 1975

PubMed

7) 島田久, 鈴木正 : アミロイド症. 腎と透析 61 (増刊号) : 573-577, 2006

 

8) Ikegaya N, Kobayashi S, Hishida A, Kaneko E, et al : Colonic dilatation due to dialysis-related amyloidosis. Am J Kidney Dis 25 : 807-809, 1995

PubMed

9) Kawano M, Muramoto H, Yamada M, Minamoto M, et al : Fatal cardiac beta 2-microglobulin amyloidosis in patients on long-term hemodialysis. Am J Kidney Dis 31 : E4, 1998

PubMed

10) Tan SY, Irish A, Winearls CG, Brown EA, et al : Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology. Kidney Int 50 : 282-289, 1996

PubMed

11) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 : S1-201, 2003

PubMed

12) Skroeder NR, Jacobson SH, Holmquist B, Kjellstrand P, et al : Beta 2-microglobulin generation and removal in long slow and short fast hemodialysis. Am J Kidney Dis 21 : 519-526, 1993

PubMed

13) Raj DS, OuwendykM, Francoeur R, Pierratos A : Beta (2) -microglobulin kinetics in nocturnal haemodialysis. Nephrol Dial Transplant 15 : 58-64, 2000

PubMed

14) Kuragano T, Inoue T, Yoh K, Shin J, et al : Effectiveness of beta (2) -microglobulin adsorption column in treating dialysis-related amyloidosis : A multicenter study. Blood purification 32 : 317-322, 2011

PubMed

15) Miyata T, Jadoul M, Kurokawa K, Van Ypersele de Strihou C : Beta-2 microglobulin in renal disease. J Am Soc Nephrol 9 : 1723-1735, 1998

PubMed

P.638 掲載の参考文献

1) 大磯ユタカ, 須田俊宏, 森昌朋, 他 : プロラクチン (PRL) 分泌過剰症の診断と治療の手引き (平成22年度改訂) 厚生労働省科学研究費補助金難治性疾患克服研究事業 間脳下垂体機能障害に関する調査研究班平成22 年度総括・分担研究報告書, pp171-178, 2011

 

2) 苛原稔 : 乳汁漏出症. 生殖医療ガイドライン 2010, 日本生殖医療学会編, pp59-62, 金原出版, 東京, 2010

 

3) Zanettini R, Antonini A, Gatto G, et al : Valvular heart disease and the use of dopamine agonist for Parkinson's disease. N Engl J Med 356 : 39-46, 2007

PubMed

P.642 掲載の参考文献

1) 木元康介, 池田俊也, 永尾光一, 他 : International Index of Erectile Function (IIEF) およびその短縮版であるIIEF5の新しい日本語訳の作成. 日本性機能学会雑誌 24 (3) : 295-308, 2009

Medical*Online

2) Bohm M, Baumhakel M, Teo K, et al : Erectile dysfunction predicts cardiovascular events in highrisk patients receiving telmisartan, ramipril, or both : The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials. Circulation 121 (12) : 1439-1446, 2010

PubMed

3) Gazzaruso C, Giordanetti S, Amici ED, et al : Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation 110 : 22-26, 2004

 

4) Palmer B, et al : Sexual dysfunction in uremia. J Am Soc Nephrol 10 : 1381-1388, 1999

PubMed

5) Mahon A, et al : The Efficacy of Sildenafil for the Treatment of Erectile Dysfunction in Male Peritoneal Dialysis Patients. Am J Kidney Dis 45 (2) : 381-387, 2005

PubMed

6) 佐々木春明, 林圭一郎, 山本健郎, 他. PDE5阻害薬の少量持続投与による血管病変に対する効果. 日本性機能学会雑誌 27 (1) : 49-55, 2012

Medical*Online

P.647 掲載の参考文献

1) 日本透析医学会 : 慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 透析会誌 45 : 301-356, 2012

 

2) Cunningham J, Locatelli F, Rodriguez M : Secondary hyperparathyroidism : pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 6 : 913-921, 2011

PubMed

3) Moallem E, Kilav R, Silver J, Naveh-Many T : RNA-Protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J Biol Chem 273 : 5253-5259, 1998

PubMed

4) Ritter CS, Finch JL, Slatopolsky EA, Brown AJ : Parathyroid hyperplasia in uremic rats precedes down-regulation of the calcium receptor. Kidney Int 60 : 1737-1744, 2001

PubMed

5) Korkor AB : Reduced binding of [3H] 1,25-dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure. N Engl J Med 316 : 1573-1577, 1987

 

6) Slatopolsky E, Finch J, Denda M, Ritter C, et al : Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 97 : 2534-2540, 1996

PubMed

7) Valdivielso JM, Cannata-Andia J, Coll B, Fernandez E : A new role for vitamin D receptor activation in chronic kidney disease. Am J Physiol Renal Physiol 297 : F1502-F1509, 2009

 

8) Fukagawa M, Yumita S, Akizawa T, Uchida E, et al : Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 23 : 328-335, 2008

PubMed

9) Raggi P, Chertow GM, Torres PU, Csiky B, et al : The ADVANCE study : a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 26 : 1327-1339, 2011

PubMed

10) Block GA, Zaun D, Smits G, Persky M, et al : Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int 78 : 578-589, 2010

 

11) Shiizaki K, Hatamura I, Negi S, Narukawa N, et al : Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia. Kidney Int 64 : 992-1003, 2003

PubMed

12) Koiwa F, Kakuta T, Tanaka R, Yumita S : Efficacy of percutaneous ethanol injection therapy (PEIT) is related to the number of parathyroid glands in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 22 : 522-528, 2007

 

P.652 掲載の参考文献

1) Hamano T, Matsui I, Mikami S, et al : Fetuin-mineral complex reflects extraosseous calcification stress in CKD. J Am Soc Nephrol 21 : 1998-2007, 2010

PubMed

2) 日本透析医学会 : 慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 日透会誌 45 : 301-356, 2012

 

3) Kakuta T, Tanaka R, Hyodo T, et al : Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis 58 : 422-431, 2011

 

4) Toussaint ND, Lau KK, Polkinghorne KR, et al : Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis : A pilot randomized controlled trial. Nephrology (Carlton) 16 : 290-298, 2011

PubMed

5) Suki WN, Zabaneh R, Cangiano JL, et al : Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72 : 1130-1137, 2007

PubMed

6) Raggi P, Chertow GM, Torres PU, et al : The ADVANCE study : a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 26 : 1327-1339, 2011

PubMed

7) EVOLVE Trial Investigators : Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367 : 2482-2494, 2012

PubMed

8) Lau WL, Leaf EM, Hu MC, et al : Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int 82 : 1261-1270, 2012

PubMed

9) O'Neill WC, Sigrist MK, McIntyre CW : Plasma pyrophosphate and vascular calcification in chronic kidney disease. Nephrol Dial Transplant 25 : 187-191, 2010

PubMed

10) Nitta K, Akiba T, Suzuki K, et al : Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis 44 : 680-688, 2004

 

11) Adirekkiat S, Sumethkul V, Ingsathit A, et al : Adirekkiat, S. et al. Sodium thiosulfate delays the progression of coronary artery calcification in haemodialysis patients. Nephrol Dial Transplant 25 : 1923-1929, 2010

PubMed

12) Meema HE, Oreopoulos DG, Rapoport A : Serum magnesium level and arterial calcification in endstage renal disease. Kidney Int 32 : 388-394, 1987

PubMed

P.657 掲載の参考文献

1) Guideline Working Group, Japanese Society for Dialysis Therapy : Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial 12 : 514-525, 2008

 

2) 日本透析医学会 : 慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 透析会誌 45 : 301-356, 2012

 

3) Fukagawa M, Yumita S, Akizawa T, Uchida E, et al ; KRN1493 study group : Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 23 : 328-335, 2008

 

4) Shoji T, Shinohara K, Kimoto E, et al : Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 19 : 179-184, 2004

 

5) Teng M, Wolf M, Ofsthun MN, et al : Activated injectable vitamin D and hemodialysis survival : a historical cohort study. J Am Soc Nephrol 16 : 1115-1125, 2005

PubMed

P.662 掲載の参考文献

1) 厚生労働科学研究費補助金 難治性疾患克服研究事業アミロイドーシスに関する調査研究班 : アミロイドーシス診療ガイドライン 2010

 

2) 日本透析医学会 : 慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 透析会誌 45 : 301-356, 2012

 

3) Dember LM, Jaber BL : Dialysis-related amyloidosis : late finding or hidden epidemic? Semin Dial 19 : 105-109, 2006

PubMed

4) 秋葉隆, 川西秀樹, 峰島三千男, 政金生人, 他 : 透析液水質基準と血液浄化器性能評価基準 2008. 透析会誌 41 : 159-167, 2008

 

5) Grooteman MPC, van den Dorpel MA, Bots ML, et al : Effect of online hemodiafiltration on all-cause mortality and cardiovasucular outocomes. J Am Soc Nephrol 23 : 1087-1096, 2012

 

6) Ok E, Asci G, Toz H, et al : Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis : results from the Turkish OL-HDF study. Nephrol Dial Transplant 28 : 192-202, 2013

PubMed

7) Gejyo F, Amano I, Ando T, et al : Survey of the effects of a column for adsorption of β2-microglobulin in patients with dialysis-related amyloidosis in Japan. Ther Apher Dial 17 : 40-47, 2013

 

P.666 掲載の参考文献

1) Cunningham J, Danese M, Olson K, et al : Effects of the calcimimetic cinacalcet HCl on cordiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68 (4) : 1793-1800, 2005

 

2) Delmas PD, Genant HK, Crans GG, et al : Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures : results from the MORE trial. Bone 33 (4) : 522-532, 2003

PubMed

3) Lenart BA, Lorich DG, Lane JM : Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358 (12) : 1304-1306, 2008

PubMed

4) Hernandez E, Valera R, Alonzo E, Bajares-Lilue M, et al : Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int 63 (6) : 2269-2274, 2003

 

5) Eriguchi R, Umakoshi J, Miura S, et al : Raloxifene ameliorates progressive bone loss in postmenopausal dialysis patients with controlled parathyroid hormone levels. Clin Nephrol 72 (6) : 423-429, 2009

PubMed

6) Tanaka M, Itoh K, Matsushita K, et al : Effects of raloxifene on bone mineral metabolism in postmenopausal Japanese women on hemodialysis. Ther Apher Dial 15 (suppl 1) : 62-66, 2011

 

7) McKane WR, Khosla S, Burritt MF, et al : Mechanism of renal calcium conservation with estrogen replacement therapy in women in early postmenopause--a clinical research center study. J Clin Endocrinol Metab 80 (12) : 3458-3464, 1995

PubMed

8) Barrett-Connor E, Mosca L, Collins P, et al ; Raloxifene Use for The Heart (RUTH) Trial Investigators : Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355 (2) : 125-137, 2006

PubMed

9) Grady D, Cauley JA, Stock JL, et al : Effect of Raloxifene on all-cause mortality. Am J Med 123 (5) : 469. e1-7, 2010

 

10) Melamed ML, Blackwell T, Neugarten J, et al : Raloxifene, a selective estrogen receptor modulator, is renoprotective : a post-hoc analysis. Kidney Int 79 (2) : 241-249, 2011

PubMed

11) Cejka D, Kodras K, Bader T, et al : Treatment of Hemodialysis-Associated Adynamic Bone Disease with Teriparatide (PTH (1-34)) : A Pilot Study. Kidney Blood Press Res 33 (3) : 221-226, 2010

PubMed

12) Mitsopoulos E, Ginikopoulou E, Economidou D, et al : Impact of long-term cinacalcet, ibandronate or teriparatide therapy on bone mineral density of hemodialysis patients : a pilot study. Am J Nephrol 36 (3) : 238-244, 2012

PubMed

P.669 掲載の参考文献

1) 林松彦, 高松一郎, 吉田理, 他 : 全国調査に基づくカルシフィラキシス診断基準の提案. 透析会誌 45 : 551-557, 2012

 

2) Selye H, Gentile G, Prioreschi P : Molt induced by calciphylaxis in the rat. Science 134 : 1876-1877, 1961

PubMed

3) Gipstein RM, Coburn JW, Adams DA, et al : Calciphylaxis in man. A syndrome of tissue necrosis and vascular calcification in 11 patients with chronic renal failure. Arch Intern Med 136 : 1273-1280, 1976

 

4) Hayashi M, Takamatsu I, Kanno Y, et al : A casecontrol study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transpl 27 : 1580-1584, 2012

 

5) Girotto JA, Harmon JW, Ratner LE, et al : Parathyroidectomy promotes wound healing and prolongs survival in patients with calciphylaxis from secondary hyperparathyroidism. Surgery 130 : 645-650, 2001

PubMed

6) Wilmer WA, Magro CM : Calciphylaxis : emerging concepts in prevention, diagnosis, and treatment. Semin Dial 15 : 172-186, 2002

PubMed

7) Papadakis JT, Patrikarea A, Digenis GE, et al : Sodium thiosulfate in the treatment of tumoral calcifications in a hemodialysis patient without hyperparathyroidism. Nephron 72 : 308-312, 1996

 

8) Yatzidis H : Successful sodium thiosulphate treatment for recurrent calcium urolithiasis. Clin Nephrol 23 : 63-67, 1985

PubMed

9) Cicone JS, Petronis JB, Embert CD, et al : Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis 43 : 1104-1108, 2004

PubMed

P.672 掲載の参考文献

1) 加藤基嗣, 他 : Helicobacter pylori : 除菌時代の胃癌罹患者の動向. Helicobacter Research 11 : 427-432, 2007

 

2) Sakuramoto S, et al : Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357 (18) : 1810-1820, 2007

 

3) Bang YJ, et al : Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER 2-positive advanced gastric or gastrooesophgeal junction cancer (ToGA) : a phase 3, openlabel, randomised controlled trial. Lancet 376 : 687-697, 2010

 

4) Wolmark N, et al : The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer : results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. JCO 11 (10) : 1879-1887, 1993

 

5) Kodera Y : A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302study). Anticancer Res 27 : 2667-2671, 2007

PubMed

P.676 掲載の参考文献

1) Shirao K, et al : Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer : Joint United States and Japan Study of UFT/LV. J Clin Oncol 22 : 3466-3474, 2004

 

2) Petrelli N, et al : A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-doseleucororin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced cdorectal carcinoma. J Clin Oncol 5 : 1879-1887, 1987

 

3) Shimada Y, et al : Phase II study of CPT-11, a new camptothecin derivative in metastatic colorectal cancer. J Clin Oncol 11 : 909-913, 1993

PubMed

4) Van Cutsem E, et al : Open-label phase III trial of anitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25 : 1658-1664, 2007

PubMed

5) Jonker DJ, et al : Cetuximab for the treatment of colorectal cancer. N Engl J Med 357 : 2040-2048, 2007

PubMed

P.680 掲載の参考文献

1) 日本肝臓学会 (編) : 肝癌診療マニュアル 第2版, 医学書院, 東京, 2010

 

2) Llovet JM, Ricci S, Mazzaferro V, et al : Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 : 378-390, 2008

PubMed

3) Cheng AL, Kang YK, Chen Z, et al : Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma : a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10 : 25-34, 2009

 

4) Shinsako K, Mizuno T, Terada T, et al : Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis : a case study. Int J Clin Oncol 15 : 512-514, 2010

PubMed

5) Kennoki T, Kondo T, Kimata N, et al : Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center. Jpn J Clin Oncol 41 : 647-655, 2011

 

P.685 掲載の参考文献

1) Oguri T, Shimokata T, Inada M, et al : Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis. Cancer Chemother Pharmacol 66 : 813-817, 2010

PubMed

2) D'Incalci M, Rossi C, Zucchetti M, et al : Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res 46 : 2566-2571, 1986

PubMed

3) Fujita K, Sunakawa Y, Miwa K, et al : Delayed elimination of SN-38 in cancer patients with severe renal failure. Drug Metab Dispos 39 : 161-164, 2011

PubMed

4) Togashi Y, Masago K, Fukudo M, et al : Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis. J Thorac Oncol 5 : 601-605, 2010

PubMed

P.689 掲載の参考文献

1) Izzedine H, Etienne-Grimaldi MC, Renee N, Vignot S, et al : Pharmacokinetics of sunitinib in hemodialysis. Ann Oncol 20 (1) : 190-192, 2009

PubMed

2) Kennoki T, Kondo T, Kimata N, Murakami J, et al : Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center. Jpn J Clin Oncol 41 (5) : 647-655, 2011

 

3) Thiery-Vuillemin A, Curtit E, Maurina T, Montange D, et al : Hemodialysis does not affect everolimus pharmacokinetics : two cases of patients with metastatic renal cell cancer. Ann Oncol 23 (11) : 2992-2993, 2012

PubMed

4) Lunardi G, Armirotti A, Nicodemo M, Cavallini L, et al : Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis : a case series. Clin Ther 31 (8) : 1812-1819, 2009

 

P.692 掲載の参考文献

1) 内藤明広, 他 : ハイリスク症例に対する乳癌治療 血液透析患者. 日本臨牀 70 (増刊号) : 7, 2012

 

2) 山中康弘 : 肝機能低下症例, 腎機能低下症例, 骨髄機能低下症例の化学療法. コンセンサス癌治療, 2010

 

3) 堀井理絵, 他 : 血液透析中の乳癌症例の臨床的検討. 日本臨床外科学会雑誌 59 (12) : 2972-2974, 1998

 

【透析療法に伴う偶発症】

P.696 掲載の参考文献

1) Buxton AE, Calkins H, et al : ACC/AHA Task Force on Clinical Data Standards. Circulation 114 : 2534, 2006

PubMed

2) Davis TR, Young BA, Eisenberg MS, et al : Outcome of cardiac arrests attended by emergency medical servies staff at community outpatient dialysis centers. Kidney Int 73 : 933, 2008

 

3) Christenson J, Andrusiek D, Everson-Stewart S, Kundenchuk P, et al : Chest compression fraction determines survival in patients with out-hospital ventricular fibrillation. Circulation 120 (13) : 1241, 2009

 

4) Aung K, Htay T : Vasopressin for cardiac arrest : a systematic review and meta-analysis. Arch Intern Med 165 (1) : 17, 2005

PubMed

5) Dorian P, Cass D, SchwartZ B, et al : Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med 346 (12) : 884, 2002

PubMed

P.700 掲載の参考文献

1) 小宅育代, 奥山寛 : 透析トラブルQ&A 空気混入と血液漏出の原因と対策について教えてください. 腎と透析 64 : 734-736, 2008

 

2) Mirski MA, Lele AV, Fitzsimmons L, et al : Diagnosis and treatment of vascular air embolism. Anesthesiology 106 : 164-177, 2007

PubMed

3) Muth CM, Shank ES : Gas embolism. N Engl J Med 342 : 476-481, 2000

PubMed

4) Toung T JK, Rossberg MI, Hutchins GM : Volume of air in a lethal venous air embolism. Anesthesiology 94 : 360-361, 2001

 

5) Walther HB, Ronald JH : Lethal air embolism following removal of a double lumen jugular vein catheter. Nephrol Dial Transplant 14 : 1850-1852, 1999

 

P.704 掲載の参考文献

1) 日本救急医学会 : 救急診療指針 改訂第4版, pp74-82, へるす出版, 東京, 2011

 

2) 日本内科学会 : 内科救急診療指針 第1版, 2011

 

3) 日本腎臓学会 : CKD診療ガイド 2012. 日腎会誌 54 (8) : 1031-1189, 2012

 

4) 中田夕香子, 田中杏, 川西智子, 他 : 透析患者の敗血症性ショック, 透析時低血圧に対する低用量AVP投与の有効性についての検討. 透析会誌 41 (11) : 779-784, 2008

 

P.708 掲載の参考文献

1) 日本透析医学会統計調査委員会 : わが国の慢性透析療法の現状 (2011年12月31日現在), 2012

 

2) Escola G, Cases A, Bastida E, et al : Uremic platelets have a functional defect affecting the interaction of von Willebrand factor with glycoprotein IIb-IIIa. Blood 76 : 1336-1340, 1990

 

3) 前島司, 高橋進, 波多野道信 : 慢性腎不全における血小板凝集能 全血血小板凝集能とグアニジン化合物. 日腎会誌 33 : 201-212, 1991

 

4) 門口啓, 乳原善文, 田上哲夫, 他 : 当院維持透析患者における腎出血10例の検討. 透析会誌 39 (suppl 1) : 997, 2006

 

5) 崔啓子, 栗田宜明, 西隆博, 他 : 当院の透析患者の四肢・体幹の特発性出血に関する検討. 透析会誌 42 : 145-149, 2009

 

6) Milutunovich J, Follette WC, Scribner BH, et al : Spontaneous retroperitoneal bleeding in patients on chronic hemodialysis. Ann Intern Med 86 : 189-192, 1977

 

7) 小川裕二郎, 平山浩一, 下畑誉, 他 : 症例による透析患者の画像診断 腎嚢胞・腎周囲出血に対する血管塞栓療法が奏効した維持血液透析症例. 臨牀透析 25 (6) : 751-757, 2009

 

P.711 掲載の参考文献

1) Hoen B, Paul-Dauphin A, Hestin D, et al : EPIBACDIAL : a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 9 : 869-876, 1998

PubMed

2) 日本透析医学会 : 慢性血液透析用バスキュラーアクセスの作製および修復に関するガイドライン (2011年版). 透析会誌 44 : 855-937, 2011

 

3) Saran R, Dykstra DM, Wolfe RA, et al : Association between vascular access failure and the use of specific drugs : the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 40 : 1255-1263, 2002

PubMed

4) Yevzlin AS, Conley EL, Sanchez RJ, et al : Vascular access outcomes and medication use : a USRDS study. Semin Dial 19 : 535-539, 2006

 

5) Hasegawa T, Elder SJ, Bragg-Gresham JL, et al : Consistent aspirin use associated with improved arteriovenous fistula survival among incident hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Clin J Am Soc Nephrol 3 : 1373-1378, 2008

PubMed

6) Crowther MA, Clase CM, Margetts PJ, et al : Lowintensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis : A randomized controlled trial. J Am Soc Nephrol 13 : 2331-2337, 2002

PubMed

7) Dember LM, Beck GJ, Allon M, et al : Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis : a randomized controlled trial. JAMA 299 : 2164-2171, 2008

PubMed

8) Dixon BS, Beck GJ, Vazquez MA, et al : Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med 360 : 2191-2201, 2009

PubMed

9) Kaufman JS, O'Connor TZ, Zhang JH, et al : Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 14 : 2313-2321, 2003

PubMed

【腎移植】

P.717 掲載の参考文献

1) Brent LA : History of Transplantation Immunology, Academic Press, Boston, 1997

 

2) Schimmer BP, Parker KL : Adrenocorticotropic hormone ; adrenocortical steroids and their synthetic analogs ; inhibitors of the synthesis and actions of adrenocortical hormones. The Pharmacological Basis of Therapeutics, 11th ed, Brunton LL, Lazo JS, Parker KL (eds), p1587, McGraw Hill, NY, 2006

 

3) Donohoue PA : The adrenal gland and its disorders. Principles and practice of pediatric endocrinology, KappyMS, Allen DB, Geffner ME (eds), p403, Charles C Thomas, Springfield, 2005

 

4) OPTN&SRTR Annual Data Report 2011 : http://optn.transplant.hrsa.gov/data/annualReport.asp

 

5) Hricik DE, O'Toole MA, Schulak JA, Herson J : Steroid-free immunosuppression in cyclosporinetreated renal transplant recipients : a meta-analysis. J Am Soc Nephrol 4 : 1300, 1993

 

6) Sandrini S, Maiorca R, Scolari F, et al : A prospective randomized trial on azathioprine addition to cyclosporine versus cyclosporine monotherapy at steroid withdrawal, 6 months after renal transplantation. Transplantation 2000 ; 69 : 1861, 2000

PubMed

7) 日本臨床腎移植学会, 腎移植臨床登録集計報告 (2011) ・2 2010年実施症例の集計報告 (2). 移植 46 (6) : 506-523, 2012

 

8) 日本臨床腎移植学会, 日本移植学会, 腎移植臨床登録集計報告 (2010) ・3 2009年経過追跡調査結果. 移植 45 (6) : 608-620, 2011

 

9) KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9 (suppl 3) : S12, 2009

 

10) Woodle ES, First MR, Pirsch J, et al : A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 248 : 564, 2008

PubMed

11) Kukla A, Chen E, Spong R, et al : Recurrent glomerulonephritis under rapid discontinuation of steroids. Transplantation 91 : 1386, 2011

PubMed

12) North American Pediatric Renal Trials and Collaborative Studies 2010 Annual Transplant Report

 

P.722 掲載の参考文献

1) Cortazar F, Molnar MZ, Isakova T, Czira ME, et al : Clinical outcomes in kidney transplant recipients receiving long-term therapy with inhibitors of the mammalian target of rapamycin. Am J Transplant 12 (2) : 379-387, 2012

PubMed

2) 打田和治 : 免疫抑制療法におけるTDMの実際. 今日の移植 (25) : 526-530, 2012

Medical*Online

3) 八木澤隆, 三重野牧子, 湯沢賢治, 他 : 腎移植臨床登録集計-2007年実施症例について. 今日の移植 22 (4) : 389-395, 2009

Medical*Online

4) Vincenti F, Friman S, Scheuermann E, et al : Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 7 : 1506-1514, 2007

PubMed

5) Kaplan B, Schold J, Meier-Kriesche HU : Long-Term Graft Survival with Neoral and Tacrolimus : A Paired Kidney Analysis. J Am Soc Nephrol 14 : 2980-2984, 2003

PubMed

6) Bunnapradist S, Peng A, Fukami S, et al : Renal allograft outcomes according to initial immunosuppressive regimen : a five year follow-up of OPTN database. Am J Transplant 5 (Suppl 11) : 251, 2005

 

7) Habib AN, Smith L, Barenbaum LL, et al : The role of maintenance immunosuppressive regimen in long term kidney transplant outcome. Am J Transplant 5 (Suppl 11) : 465, 2005

 

8) Nashan B : Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors? Transplant Review 23 ; 47-52, 2009

PubMed

P.726 掲載の参考文献

1) 白木公康 : ミゾリビンの抗サイトメガロウイルス効果. 今日の移植 21 : 272-278, 2008

Medical*Online

2) Akiyama T, et al : Mizoribine in combination therapy with tacrolimus for living donor renal transplantation : analysis of a nationwide study in Japan. Transplant Proc 37 : 843-845, 2005

PubMed

3) Stypinski D, et al : Safety, tolerability and pharmacokinetics of higher-dose mizoribine in healthy male volunteers. British Journal of Clinical Pharmacology 63 : 459-468, 2007

PubMed

4) Nishimura K, et al : Excellent results with high-dose mizoribine combined with cyclosporine, corticosteroid, and basiliximab in renal transplant recipients : multicenter study in Japan. Transplant Proc 44 : 147-149, 2012

PubMed

5) Takahara S, et al : A prospective, randomized comparative trial of mizoribine versus mycophenolate mofetil in combination therapy with tacrolimus for living donor renal transplantation. Clin Exp Nephrol (in press)

 

6) Ota H, et al : A novel enzymatic method for measuring mizoribine 5'-monophosphate levels in serum. Journal of bioscience and bioengineering 106 : 511-514, 2008

PubMed

7) 平光高久, 他 : ミゾリビン血中濃度の周術期詳細研究. 今日の移植 21 : 657-659, 2008

Medical*Online

8) 市川靖二 : 維持免疫抑制剤ミゾリビン. 腎移植における免疫抑制療法, pp125-142, 日本医学館, 東京, 1998

 

P.730 掲載の参考文献

1) Kagaya H, Inoue K, Miura M, et al : Influence of UGT1A8 and UGT3B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 63 : 279-288, 2007

PubMed

2) Halloran PF : Immunosuppressive drugs for kidney transplantation. N Engl J Med 351 : 2715-2720, 2004

PubMed

3) 佐藤滋 : 腎移植に使用される分子標的薬. 腎と透析 67 : 632-637, 2009

Medical*Online

4) Satoh S, Tada H, Murakami M, et al : Circadian pharmacokinetics of mycophenolic acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients. Transplantation 82 : 486-493, 2006

PubMed

5) Kuypers DRJ, Meur YL, Cantarovich, et al : Consensus reports on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol 5 : 341-358, 2010

PubMed

P.734 掲載の参考文献

1) USRDS 2012 home page, data of transplantation. http://www.usrds.org/2012/pdf/v2_ch7_12.pdf

 

2) Meier-Kriesche HU, Li S, Gruessner RW, et al : Immunosuppression : evolution in practice and trends, 1994-2004. Am J Transplant 6 (part 2) : 1111-1131, 2006

 

3) 吉村了勇, 昇修治 : 代謝拮抗薬 : アザチオプリン. 腎移植のすべて, 高橋公太編, pp271-272, メジカルビュー社, 東京, 2009

 

4) 徳本直彦, 田邊一成 : 免疫抑制療法アザチオプリン. 移植ガイドブック, 東間紘, 高橋公太編, pp142-145, 中外医学社, 東京, 2000

 

5) Danovitch GD : Immunosuppressive medications and protocols for kidney transplantation. Handbook of kidney transplantation, Danovitch GM (ed), pp72-134, Lippincott Williams & Wilkins, Philadelphia, 2005

 

6) 楊國昌 : 腎炎・ネフローゼの免疫抑制療法エネルギー代謝を標的としたプリン代謝拮抗薬. 医学のあゆみ 237 (9) : 865-869, 2011

 

7) Yoshida K, Endo T, Saito T, et al : Factors contributing to long graft survival in non-heart-beating cadaveric renal transplantation in Japan : a singlecenter study at Kitasato University. Clin Transplant 16 : 397-404, 2002

 

8) Clayton PA, McDonald SP, Chapman JR, Chadban SJ : Mycophenolate versus azathioprine for kidney transplantation : a 15-year follow-up of a randomized trial. Transplantation 94 : 152-158, 2012

PubMed

P.738 掲載の参考文献

1) Starzl TE, et al : Cyclophosphamide and human organ transplantation. Lancet 2 : 70-74, 1971

PubMed

2) Yadav RV, et al : Cyclophosphamide in renal transplantation. Transplantation 45 : 421-424, 1988

PubMed

3) Turk JL, et al : Functional aspects of the selective depletion of lymphoid tissue by cyclophosphamide. Immunology 23 : 493-501, 1972

PubMed

4) Houssiau FA, et al : The 1-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 69 : 61-64, 2010

PubMed

5) Tsuruya K, et al : Combination therapy using prednisolone and cyclophosphamide slows the progression of moderately advanced IgA nephropathy. Clin Nephrol 53 : 1-9, 2000

PubMed

6) Alarabi A, et al : Plasmapheresis in HLA-immunosensitized patients prior to kidney transplantation. Int J Artif Organs 20 : 51-56, 1997

PubMed

P.741 掲載の参考文献

1) 遠藤忠雄 : 腎移植に使用される薬剤 デオキシスパガリン (塩酸グスペリムス). 腎と透析 41 (増刊号) : 642-644, 1996

 

2) Takeuchi T, Iinuma H, Kunimoto S, et al : A new antitumor antibiotic, spergualin : Isolatin and antitumor activity. J Antibiot 34 : 1619-1621, 1987

 

3) 雨宮浩 : Deoxyspergualinの腎移植への応用. 今日の移植 5 : 121-124, 1992

Medical*Online

4) Amemiya H, Suzuki S, Ota K, et al : Multicentre clinical trial of antirejection pulse therapy with deoxyspergualin in kidney transplant patients. Int J Clin Pharm Res 11 : 175-182, 1991

 

5) 雨宮浩 : 治療法をめぐる最近の進歩 : デオキシスパガリン. 医学のあゆみ (別冊号) : 325-327, 1995

 

6) Tanabe K, Tokumoto T, Ishikawa N, et al : Effect of deoxyspergualin on the long-term outcome of renal transplantation. Transplant Proc 32 : 1745-1746, 2000

 

P.746 掲載の参考文献

1) 原田浩 : 〔拒絶反応の診断と治療〕拒絶反応のメカニズム T-cell-mediated rejection. 腎移植・血管外科 19 : 104-112, 2008

 

2) Abbas AK, Lichitman AH, Pillai S : Cellural and Molecular Immunology 6th edition, pp 267-301, Saunders/Elsevier, Philadelphia, 2007

 

3) Novartis社シムレクトに関する総合製品情報概要

 

4) 斎藤和英 : 特集-免疫抑制剤の新たなる展開Basiliximabの現状. 移植 38 : 394-400, 2003

 

5) Vondran FW, Timrott K, Tross J, Kollrich S, et al : Impact of Basiliximab on regulatory T-cells early after kidney transplantation : down-regulation of CD25 by receptor modulation. Transpl Int 23 : 514-523, 2010

PubMed

P.749 掲載の参考文献

1) Sawada T, Fuchinoue S, Teraoka S : Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation 74 (9) : 1207-1210, 2002

 

2) Kohei N, Hirai T, Omoto K, Ishida H, et al : Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant 12 (2) : 469-476, 2012

PubMed

3) Irei T, Ohdan H, Zhou W, et al : The persistent elimination of B cells responding to blood group A carbohydrates by synthetic group A carbohydrates and B-1 cell differentiation blockade : novel concept in preventing antibody-mediated rejection in ABO-incompatible transplantation. Blood 110 : 4567-4575, 2007

 

4) Kim DH, Jung HD, Kim JG, et al : FCγ-R3a gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 108 (8) : 2720-2725, 2006

 

5) Tanabe K, Ishida H, Shimizu T, et al : Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens. Contrib Nephrol 162 : 61-74, 2009

PubMed

6) Vo AA, Lukovsky M, Toyoda M, et al : Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 359 : 242-251, 2008

PubMed

7) Vo AA, Peng A, Toyoda M, et al : Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 89 : 1095-1102, 2010

PubMed

8) Kaposztas Z, Podder H, Mauiyyedi S, et al : Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant 23 : 63-73, 2009

PubMed

9) Zarkhin V, Li L, Kambham N, et al : A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant 8 : 2607-2617, 2008

PubMed

P.753 掲載の参考文献

1) Mourad G, Morelon E, et al : The role of thymoglobulin induction in kidney transplantation : an update. Clin Transplant 26 : E450-E464, 2012

PubMed

2) Deeks ED, Keating GM : Rabbit antithymocyte globulin (Thymoglobulin) a review of its use in the prevention and treatment of acute renal allograft rejection. Drugs 69 (11) : 1483-1512, 2009

PubMed

3) Hardinger KL, Brennan DC, Klein CL : Selection of induction therapy in kidney transplantation. Transplant Intern 31 DEC 2012 DOI : 10.1111/tri. 12043

 

4) Brennan DC, Schnitzler MA : Long-term results of rabbit antithymocyte globulin and basiliximab induction. N Engl J Med 359 : 1736, 2008

PubMed

5) Mueler TF : Mechanisms of action of thymoglobulin. Transplantation 84 (suppl 11) : S5, 2007

 

P.756 掲載の参考文献

1) Kubak BM, Maere CL, Pegues DA, et al : Infection in Kidney Transplantation. Handbook of Kidney Transplantation, pp290-309, Lippincott Williams & Wilkins, Philadelphia, 2005

 

2) 三留淳, 山本裕康 : 発熱. 腎移植のすべて, pp404-406, メジカルビュー社, 東京, 2009

 

3) KDIGO Guideline. Other Infections. Am J Transplant 9 (suppl 3) : S59-S62, 2009

 

4) 臨床腎移植学会 : 腎移植後サイトメガロウイルス感染症の診療ガイドライン 2011. http://www.jscrt.jp/pdf_file/guide_cmv.pdf

 

5) Yagisawa T, Nakada T, Takahasi K, et al : Acute hemorrhagic cystitis caused by adenovirus after kidney transplantation. Urol Int 54 : 142-146, 1995

 

P.760 掲載の参考文献

1) Lahav M, Regev A, Ra'anani P, Theodor E : Intermittent administration of furosemide vs continuous infusion preceded by a loading dose for congestive heart failure. Chest 102 : 725-731, 1992

PubMed

2) Heinze G, Mitterbauer C, Regele H, Kramar R, et al : Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 3 : 889-899, 2006

PubMed

3) Philipp T, Martinez F, Geiger H, Moulin B, et al : Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients : results from SECRET. Nephrol Dial Transplant 3 : 967-976, 2010

PubMed

4) Costello-Bperrigter LC, SmithWB, Boerriger G, et al : Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol renal Pysiol 290 : 273-278, 2006

 

5) 西慎一, 長谷川進, 他 : 臓器移植とアフェレーシス. 臨牀透析 15 : 723-728, 1999

 

6) 君川正昭, 江口圭, 峰島三千男, 他 : 二重濾過血漿交換療法 (DFPP) における指摘置換液量・置換アルブミン濃度. 透析会誌 34 : 1227-1238, 2001

 

P.763 掲載の参考文献

1) 相田紘一朗, 佐々木秀郎, 江東邦夫, 北島和樹, 他 : 術中の被膜切開によりPage kidneyを回避できた献腎移植の1例. 聖マリアンナ医科大学雑誌 39 : 263-266, 2012

Medical*Online

2) 中村美智子, 原田浩, 平野哲夫, 宇野仁揮, 他 : 誤って尿管を腹膜に吻合した献腎移植の1例. 腎移植・血管外科 21 (2) : 199-203, 2010

 

3) Lucewicz A, Isaacs A, Allen RD, Lam VW, et al : Torsion of intraperitoneal kidney transplant. ANZ J Surg 82 (5) : 299-302, 2012

PubMed

4) 武田朝美, 両角國男 : 〔臓器移植に伴う腎障害〕薬物による (主としてカルシニューリン阻害薬) による腎障害. 腎と透析 59 : 1005-1011, 2005

 

5) Manfro RC, Comerlato L, Berdichevski RH, et al : Nephrotoxic acute renal failure in a renal transplant patient with recurrent lymphocele treated with povidone-iodine irrigation. Am J Kidney Dis 40 : 655-657, 2002

 

6) Li SD, Wang QT, Chen WG : Treatment of urinary lithiasis following kidney transplantation with extracorporeal shock-wave lithotripsy. Chin Med J (Engl) 124 (9) : 1431-1434, 2011

PubMed

P.767 掲載の参考文献

1) KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients : Hematological Complications. Am J Transplant 9 (suppl 3) : S97-S101, 2010

 

2) Malyszko J, Malyszko JS, Mysliwiec M : A possible role of hepcidin in the pathogenesis of anemia among kidney allograft recipients. Transplant Proc 41 : 2079-2081, 2009

 

3) Vanrenterghem Y, Ponticelli C, Morales JM, et al : Prevalence and management of anemia in renal transplant recipients : a European survey. Am J Transplant 3 : 835-845, 2003

PubMed

4) Martinez F, Kamar N, Pallet N, et al : High dose epoetin beta in the first weeks following renal transplantation and delayed graft function : Results of the Neo-PDGF Study. Am J Transplant 10 : 1695-1700, 2010

PubMed

5) Choukroun G, Kamar N, Dussol B, et al : Correction of postkidney transplant anemia reduces progression of allograft nephropathy. J Am Soc Nephrol 23 : 360-368, 2012

PubMed

P.771 掲載の参考文献

1) Calabuig AS, Guirado L, Ramos D : Prognostic significance and diagnosis of proteinuria in renal transplantation. Transplantation Reviews 26 : 30-35, 2012

PubMed

2) Fresnado GF, Plaza JJ, Plumed JS, Guajardo AS, et al : Proteinuria : a new marker of long-term graft and patient survival in kidney transplantation. Nephrol Dial Transplant 19 (suppl 3) : iii48-iii51, 2004

 

3) Diekmann F, Andres A, Oppenheimer F : mTOR inhibitor-associated proteinuria in kidney transplant recipients. Transplantation Reviews 26 : 27-29, 2012

PubMed

4) Knoll GA : Proteinuria in kidney transplant recipients : prevalence, prognosis, and evidence-based management. Am J Kidney Dis 54 : 1131-1144, 2009

PubMed

5) Ruiz JC, Sanchez-Fructuoso A, Zarraga S : Management of proteinuria in clinical practice after kidney transplantation. Transplant Rev 26 : 36-43, 2012

PubMed

P.774 掲載の参考文献

1) 血尿診断ガイドライン検討委員会 : 血尿診断ガイドライン. 日腎会誌 48 (suppl) : 1-34, 2006

 

2) 三浦正義, 藤井寛, 服部元史, 佐久間康成, 他 : 腎移植のすべて, 高橋公太編, pp312-322, 362-365, 389-392, メジカルビュー社, 東京, 2009

 

3) Yagisawa T, et al : Acute hemorrhagic cystitis caused by adenovirus after kidney transplantation. Urol Int 54 : 142-146, 1995

PubMed

4) 石川暢夫 : 腎移植ハンドブック, 東間紘, 高橋公太, 編, pp267-268, 中外医学社, 東京, 2000

 

P.777 掲載の参考文献

1) 腎移植後内科・小児科系合併症の診療ガイドライン 2011, 日本臨床腎移植学会編, 2011

 

2) 高尿酸血症・痛風の治療ガイドライン 2010, 日本痛風・核酸代謝学会編, 2010

 

3) KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. Am J Transplant 9 (suppl 3) : S1-S157, 2009

 

4) Obermayr RP, et al : Elevated uric acid increases the risk for kidney diseases. J Am Soc Nephrol 19 : 2407-2413, 2008

 

5) Goicoechea M, et al : Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5 (8) : 1388-1393, 2010

PubMed

P.782 掲載の参考文献

1) 日本動脈硬化学会編 : 動脈硬化性疾患予防ガイドライン 2008, 協和企画, 東京, 2008

 

2) 日本腎臓学会編 : CKD診療ガイド 2012, pp76-78, pp114-115, 東京医学社, 東京, 2012

 

3) Kasiske B, Cosio FG, Beto J, Bolton K, et al ; National Kidney Foundation. Clinical practice guideline for managing dyslipidemias in kidney transplant patients : a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplnt 7 (4 Suppl) : 13-53, 2004

 

4) KDIGO Work Group : Chapter 16 : Hypertension, Dyslipidemias, Tobacco Use, and Obesity. Am J Transplant 9 (suppl 3) : S71-79, 2009

 

5) 日本臨床腎移植学会ガイドライン作成委員会編 : 腎移植後内科・小児科系合併症の診療ガイドライン 2011, pp30-36, 日本医学館, 東京, 2011

 

P.786 掲載の参考文献

1) 赤血球増加症 (多血症) (http://www.nms.co.jp/naika2/blood/pv.html)

 

2) Vardiman J, Hyjek E : World health organization classification, evaluation, and genetics of the myeloproliferative neoplasm variants. Hematology Am Soc Hematol Educ Program 2011 : 250-256, 2011

PubMed

3) Malyszko J, Oberbauer R, Watschinger B : Anemia and erythrocytosis in patients after kidney transplantation. Transplant Int 25 : 1013-1023, 2012

PubMed

4) Gossmann J, Burkhardt R, Harder S, et al : Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway. Kidney Int 60 : 83-86, 2001

PubMed

5) Satoh S, Kaneko T, Seino K, et al : Angiotensinconverting enzyme inhibitor-induced anemia and treatment for erythrocytosis in renal transplant recipients. Jpn J Nephrol 37 : 343-347, 1995

 

P.790 掲載の参考文献

1) 駒場大峰, 深川雅史 : 腎移植患者のミネラル代謝におけるFGF23の役割. 腎と透析 72 : 355-360, 2012

Medical*Online

2) Kawarazaki H, Shibagaki Y, Fukumoto S, et al : The relative role of fibroblast growth factor 23 and parathyroid hormone in predicting future hypophostemia and hypercalcemia after living donor kidney transplantation : a 1-year prospective observational study. Nephrol Dial Transplant 26 : 2691-2695, 2011

PubMed

3) Gutierrez OM, Mannstadt M, Isakova T, et al : Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359 : 584-592, 2008

PubMed

4) Isakova T, Xie H, Yang W, et al : Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305 : 2432-2439, 2011

 

5) Wolf M, Molnar MZ, Amaral AP, et al : Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 22 : 956-966, 2011

PubMed

6) 富永芳博 : わが国におけるSHPTに対するPTxの現況. 透析会誌 45 (suppl 1) : 526, 2012

 

P.795 掲載の参考文献

1) 植木常雄 : 尿路感染症. 腎移植感染症マニュアル, 後藤憲彦編, pp78-81, 東京医学社, 東京, 2013

 

2) 原田浩 : 特集透析患者, 移植患者の感染症へのアプローチ. 腎と透析 70 (6) : 915-921, 2011

 

3) KDIGO Clinical practice Guideline for the care of kidney transplant recipients. Am J Transplant 9 (suppl 3) : chaper 14, 2009

 

P.799 掲載の参考文献

1) Washington manual of medical rherapeutics, 33rd ed, Lippincott Williams Wilkins, 2010

 

2) 青木眞 : レジデントのための感染症診療マニュアル 第2版, 医学書院, 東京, 2008

 

3) Am J Transplant 9 (suppl 3) : 2009

 

4) Danovitch GM : Handbook of Kidney Transplantation, fifth ed,

 

5) Goto N, Oka S : Pneumocystis jirovecii pneumonia in kidney transplantation. Transplant Infectious Disease 13 : 551-558, 2011

PubMed

P.804 掲載の参考文献

1) 日本結核病学会 : 結核診療ガイドライン改訂第2版, 南江堂, 東京, 2012

 

2) 森亨, 他 : 現場で役に立つクォンティフェロンTBゴールド使用の手引き, 結核予防会, 2011

 

P.808 掲載の参考文献

1) 胃潰瘍ガイドラインの適用と評価に関する研究 (編) : EBMに基づく胃潰瘍診療ガイドライン 2009 第2版-H. pylori二次除菌保険適用対応-, じほう, 東京, 2009

 

2) Asaka M, et al : Follow-up survey of a large-scale multicenter, double-blind study of triple therapywith lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. J Gastroenterol 38 (4) : 339-347, 2001

 

3) Asaka M, et al : A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 6 (3) : 254-261, 2001

PubMed

4) Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers. J Clin Pharmacol 52 (8) : 1265-1272, 2012

 

P.813 掲載の参考文献

1) Said A, Safdar N, Wells J, et al : Liver disease in renal transplant recipients. Kidney transplantation, principle and practice, 6th ed, Morris PJ and Knechtle SJ (eds), pp508-533, Saunder Elsevier, Philadelphia, 2008

 

2) 滝川一, 恩地森一, 高森頼雪, 他 : DDW-J 2004ワークショップ薬物性肝障害診断基準の提案. 肝臓 46 : 85-90, 2005

 

3) 厚生労働省 : 重篤副作用疾患別対応マニュアル薬物性肝障害 http://www.mhlw.go.jp/topics/2006/11/tp1122-1.i01.pdf

 

4) 日本肝臓学会肝炎診療ガイドライン作成委員会 : C型肝炎治療ガイドライン (第1版). 肝臓 53 : 355-395, 2012

 

5) Hu TH, Tsai MC, Chien YS, et al : A novel experience of antiviral therapy for chronic hepatitis B in renal transplant recipients. Antivir Ther 17 : 745-753, 2012

PubMed

P.817 掲載の参考文献

1) 日本臨床腎移植学会ガイドライン作成委員会編 : 腎移植後内科・小児科系合併症の診療ガイドライン 2011, 日本医学館, 東京, 2011

 

2) Morris PJ, Knechtle SJ : Kidney Transplantation 6th ed, pp331-341, Saunders Elsevier, Philadelphia, 2008

 

3) Mangray M, et al : Hypertension after kidney transplant. Am J Kidney Dis 57 : 331-341, 2011

PubMed

P.822 掲載の参考文献

1) 西慎一, 下条文武 : 慢性腎臓病と腎移植. 日本移植学会誌 42 : 342-346, 2007

 

2) Tsai JP, et al : Long term impact of pretransplant and posttransplant diabetes mellitus on kidney transplant outcomes. World J Surg 35 (12) : 2818-2825, 2011

PubMed

3) 日本移植学会編 : 臓器移植ファクトブック 2010 (日本移植学会ホームページ収載)

 

4) Vincenti F, et al : Diabetes Incidence after Renal Transplantation study. Am J Transplant 7 : 1, 2007

PubMed

5) KDIGO Clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9 (supple 3) : 66-70, 2009

 

6) 日本臨床腎移植学会編 : 臨床腎移植学会の内科小児科合併症ガイドライン 2011, 日本医学館, 東京, 2011

 

7) Bilous R, et al : The effect of pancreas transplantation on the glomerular structure of renal allografts in patients with insulin dependent diabetes. N Engl J Med 321 : 80-85, 1989

PubMed

【腎不全におけるくすりの使い方】 ( 表 )

P.827 掲載の参考文献

1) Penn I : Cancer and Transplantation : Complication of Organ Transplantation, Immunology Series 32, Toledo-Pereyra LH (ed), pp237-251, Marcel Dekker, New York and Basel, 1987

 

2) Kasiske BL, Snyder JJ, Gilbertson DT, et al : Cancer after kidney transplantation in the United States. Am J Transplant 4 : 905-913, 2004

PubMed

3) Buell JF, Gross TG, Woodle ES : Malignancy after transplantation. Transplantation 80 (2 suppl) : S254-264, 2005

 

4) Wong G, Chapman JR, Craig JC : Cancer screening in renal transplant recipients : what is the evidence? Clin J Am Soc Nephrol 3 (suppl 2) : S87-S100, 2008

 

5) 今西正昭, 国方聖司, 秋山隆弘, 栗田孝 : 当科における腎移植後の悪性腫瘍7例の検討および本邦における腎移植後の悪性腫瘍の統計. 移植 31 (2) : 100-107, 1996

Medical*Online

6) Hoshida Y, Tsukuma H, Yasunaga Y, et al : Cancer risk after renal transplantation in Japan. Int J Cancer 71 : 517-520, 1997

PubMed

P.831 掲載の参考文献

1) 白木公康, 大黒徹 : 抗ウイルス薬の作用機序. 日本臨牀 70 : 536-543, 2012

Medical*Online

2) 日本臨床腎移植学会サイトメガロウイルス感染症ガイドライン委員会 : 腎移植後サイトメガロウイルス感染症の診療ガイドライン 2011, 日本医学館, 東京, 2011

 

3) 白木公康, 大黒徹 : 抗ヘルペスウイルス薬. 単純ヘルペスウイルス, 水痘帯状疱疹ウイルス. 臨床と微生物 40 : 629-635, 2013

 

4) Matthes-Martin S, et al : European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation : summary of ECIL-4 (2011). Transpl Infect Dis 14 (6) : 555-563, 2012

PubMed

5) Kuypers DRJ : Management of polyomavirus-associated nephropathy in renal transplant recipients. Nature Reviews Nephrology 8, 390-402, 2012

PubMed

【輸液薬・透析液・補充液・その他】

P.866 掲載の参考文献

1) 宮田剛 : 基本的栄養輸液処方の考え方. 内科 109 : 216-222, 2012

 

2) Zeeki S, Culkin A, Gabe SM, et al : Refeeding hypophosphatemia is more common in enteral than parenteral feeding in adult in patients. Clin Nutr 20 : 365-368, 2011

 

3) Cano NJM, Aparicio M, Brunori G, et al : ESPEN guidelines on parenteral nutrition : Adult renal failure. Clin Nutr 28 : 401-414, 2009

PubMed

4) 熊谷裕通 : 輸液はどうする? 若手医師のための透析診療のコツ, 加藤明彦編, pp69-73, 文光堂, 東京, 2011

 

P.872 掲載の参考文献

1) 透析療法合同専門委員会編 : 血液浄化療法ハンドブック 改訂第5版, 協同医書出版, 東京, 2008

 

2) Van Stone JC, Bauer J, Carey J : The effect of dialysate sodium concentration on body fluid distribution during hemodialysis. Trans Am Soc Artif Intern Organs 26 : 383-386, 1980

PubMed

3) Daugirdas JT, Ing TS (eds) : Handbook of Dialysis, Lippincott Williams & Wilkins, Philadelphia, 2007

 

4) Henrich WL, Hunt JM, Nixon JV : Increased ionized calcium and leftventricular contractility during hemodialysis. N Engl J Med 310 : 19-23, 1984

 

5) 秋葉隆, 川西秀樹, 峰島三千男, 政金生人, 他 : 透析液水質基準と血液浄化器性能評価基準 2008. 透析会誌 41 : 159-167, 2008

 

6) Mazairac AH, de Wit CA, et al : Effect of hemodiafiltration on quality of life over time. Clin J Am Soc Nephrol 8 : 82-89, 2013

 

7) Maduell F, et al ; ESHOL Study Group : High-efficiency postdilution online hemodiafiltraion reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol 24 (3) : 487-497, 2013

 

P.876 掲載の参考文献

1) 日本薬局方, pp2744-2746

 

P.880 掲載の参考文献

1) Valero R, Cabrer C, et al : Normothermic recirculation reduces primary graft function of kidneys obtained from non-heart beating donors Transplant Int 13 : 303-310, 2000

PubMed

2) Metzer R, Deimonico F, Feng S, et al : Expanded criteria donors for kidney transplantation. Am J Transplant 3 : 114, 2003

 

3) Matsuoka L, Shah T, Aswad S, et al : Pulsatile perfusion reduces the incidence of delayed graft function in expanded criteria donor kidney transplantation. Am J Transplant 6 : 1473-1478, 2006

PubMed

4) Renkins JM, Rouflart MJ, Christiaans MHL, et al : Outcome of nonheart-beating donor kidneys with prolonged delayed graft function after transplantation. Am J Transplant 5 : 2704-2709, 2005

 

5) Moers C, Smits JM, Maathuis M-H, et al : Machine perfusion or cold storage in deceased-donor kidney transplantation. The New England Journal of Medicine 360 (1) : 7-19, 2009

 

6) Matsuno N, Sakuai E, Tamaki I, et al : Effect of machine perfusion preservation versus cold storage on the function of kidney from non-heart beating donors Transplantation 57 : 293-294, 1994

 

7) Matsuno N, Sakurai E, Tamaki I, et al : Effectiveness of machine perfusion preservation as a viability determination method for kidneys. Procured from non-heart-beating donors. Tranpl Proc 26 (4) : 2421-2422, 1994

PubMed

8) Matsuno N, Sakurai E, Uchiyama M, et al : Role of machine perfusion preservation in kidney transplantation from non-heart beating donors. Clin Transplant 12 : 1-4, 1998

 

9) Light J, Gage F, Kowaiski AE, et al : Immediate function and cost comparison between static and pulstile preservation kidney recipient. Clin Transplant 10 : 233-235, 1996

 

10) Sung RS, Christensen LL, Leichtman AB, et al : Determinats of discard of expanded criteria donor kidneys : Impact of biopsy and machine perfusion. Am J Transplant 8 : 783-792, 2008

 

11) Belzer FO, Ashby BS, Huang JS, et al : the ethiology of rising perfusion pressure in isolated organ perfusion. Ann Surgery 268 : 382-391, 1968

 

12) Hoffmann RM, Strata RJ, DAlessandro AM, et al : Combined cold storage-perfusion preservation with a new synthetic perfusate. Transplantation 47 : 32-37, 1989

 

13) Hosgood SA, Nicholson HF, Nicholson ML. : Oxygenated kidney preservation techniques. Transplantation 93 : 455-459, 2012

PubMed

14) Hosgood SA, Nicholson ML : First in man renal transplantation after ex vivo normothermic perfusion. Transplantation 92 : 735-738, 2011

PubMed

15) Iwai S, Kikuchi T, Kasahara N, Teratani T, : Impact of normothermic preservation with extracellular type solution containing trehalose on rat kidney grafting from a cardiac death donor. PLoS One 7 (3) : e33157, 2012

PubMed

P.887 掲載の参考文献

1) Craig W : Pharmacokinetic/pharmacodynamic parameters : rationale for antibacterial dosing of mice and men. Clin Infect Dis 26 : 1-12, 1998

PubMed

2) 日本化学療法学会/日本TDM 学会編 : 抗菌薬TDMガイドライン, 杏林舎, 東京, 2012

 

3) 辻本雅之, 他 : 尿毒症血清中の蛋白結合阻害因子の影響について. 日透医会誌 16 : 190-195, 2001

 

4) Reidenberg MM, Affrime M : Influence of disease on binding of drugs to plasma proteins. Ann N Y Acad Sci 226 : 115-126, 1973

PubMed

5) Hirata S, et al : Elevated serum vancomycin concentrations after oral administration in a hemodialysis patient with pseudomembranous colitis. Jpn J Clin Pharmacol Ther 34 : 87-90, 2003

 

6) Ruschitzka F, et al : Acute heart transplant rejection due to Saint John's wort. Lancet 355 : 548-549, 2000

PubMed

書評を投稿する